product_test_dtl_id,test_parameter_name,test_code,standard_value_type,standard_value_from,standard_value_to
128308,<p>SPECIFIC OPTICAL ROTATION</p>,ABACAVIR-SULPHATE-(HETERO)-IP-12537,alphanumeric,-32.0°, -38.0°
128285,<p>SPECIFIC OPTICAL ROTATION</p>,ABACAVIR-SULPHATE-IP-12535,alphanumeric,-32.0°, -38.0°
128675,<p>SPECIFIC OPTICAL ROTATION</p>,ACARBOSE-IP-12569,alphanumeric,+168°, +183°
128687,THICKNESS,"ACCETRAM-TABLET-(ACCENT,-SOLAN)-USP-12570",na,NULL,4.30 MM ±0.2 MM
128706,MELTING POINT,ACEBROPHYLLINE-GENERAL-12572,alphanumeric,215°, 217°
128843,<p>AVERAGE WEIGHT</p>,ACEFLEX-TH-TABLET-(ZEE)-GENERAL-12582,na,NULL,234 MG ± 7.5%
129067,<p>IDENTIFICATION B</p>,ACETYLCYSTEINE-BP-12604,alphanumeric,104°, 110°
129077,<p>SPECIFIC OPTICAL ROTATION</p>,ACETYLCYSTEINE-BP-12604,alphanumeric,+21.0°, +27.0°
129088,OPTICAL ROTATION,ACETYLCYSTEINE-USP-12605,alphanumeric,+21.0°, +27.0°
129171,AVERAGE WEIGHT OF 10 CONTAINERS,ACICLOVIR-FOR-INJECTABLE-SOLUTION-(KWALITY)-BP-12613,na,NULL,30°MG ± 10%
129236,HARDNESS,ACICLOVIR-TABLET-(KWALITY)-IP-12618,na,NULL,NLT 4.0 KG/CM²
129309,CONGEALING TEMPERATURE,ACRYSOL-K-150-GENERAL-12629,alphanumeric,5, 15°C
129539,<p>SPECIFIC OPTICAL ROTATION</p>,ADENOSINE-IP-12654,alphanumeric,-45.0°, -49.0°
129604,TENSILE STRENGTH WIDTH,ADHESIVE-PLASTER-(DRUG-CODE-R006)-GENERAL-12659,alphanumeric,NLT,11.0 GM/M²
129619,TENSILE STRENGTH WIDTH,ADHESIVE-PLASTER-7.5-X-10-(JAMMU-GOVT.)-GENERAL-12661,alphanumeric,NLT,11.0 GM/M²
129634,TENSILE STRENGTH WIDTH,ADHESIVE-PLASTER-SIZE--(AP-/-TEL)-GENERAL-12663,alphanumeric,NLT,11.0 GM/M²
129691,<p>SPECIFIC OPTICAL ROTATION</p>,ADRENALINE-BITARTRATE-IP-12670,alphanumeric,-50°, -54°
130003,HARDNESS,ALBENDAZOLE-TABLET-(KWALITY)-IP-12701,na,NULL,NLT 8.0 KG/CM²
129993,HARDNESS,ALBENDAZOLE-TABLET-(KWALITY)-USP-12700,alphanumeric,NLT,6.0 KG/CM²
130103,NET CONTENT PER BOTTLE,ALGARD-ID-50-GENERAL-12713,na,NULL,1010±10 ML
130102,<p>WEIGHT PER ML</p>,ALGARD-ID-50-GENERAL-12713,na,NULL,1.00° ±0.05
130109,NET CONTENT PER BOTTLE,ALGARD-NAHS-GENERAL-12714,na,NULL,505 ± 5 ML
130107,<p>WEIGHT PER ML</p>,ALGARD-NAHS-GENERAL-12714,na,NULL,1.00 ± 0.05
130092,NET CONTENT PER BOTTLE,ALGARD-R-82-GENERAL-12711,na,NULL,1000± 10 ML
130115,NET CONTENT PER BOTTLE,ALGARD-R-82-GENERAL-12715,na,NULL,1010±10 ML
130113,<p>WEIGHT PER ML</p>,ALGARD-R-82-GENERAL-12715,na,NULL,1.00  ± 0.05
130138,IDENTIFICATION A (OPTICAL ROTATION),ALL-RAC-ALPHA-TOCOPHEROL-GENERAL-12718,alphanumeric,-0.01°, +0.01°
130189,OPTICAL ROTATION,ALLANTOIN-(SPB-PHARMA)-GENERAL-12722,alphanumeric,-0.10°, +0.10°
130164,OPTICAL ROTATION,ALLANTOIN-BP-12720,alphanumeric,-0.1°, +0.1°
130176,OPTICAL ROTATION,ALLANTOIN-IP-12721,alphanumeric,-0.10°, +0.10°
130311,<p>SPECIFIC OPTICAL ROTATION</p>,ALPHA-ARBUTIN-GENERAL-12735,alphanumeric,+174.0°, +186.0°
130322,<p>SPECIFIC OPTICAL ROTATION</p>,ALPHA-BETA-ARTEETHER-IP-12736,alphanumeric,+100°, +120°
130344,MELTING RANGE,ALPHA-LIPOIC-ACID-USP-12738,alphanumeric,60.0°, 62.0°
130345,OPTICAL ROTATION,ALPHA-LIPOIC-ACID-USP-12738,alphanumeric,-1.0°, +1.0°
130390,BACTERIAL ENDOTOXINS,ALPOSTIN-INJECTION-(SAMARTH)-IP-12742,na,NULL,NMT 5 EU/100 µg
130379,BACTERIAL ENDOTOXINS,ALPOSTIN-INJECTION-(SAMARTH)-USP-12741,alphanumeric,NMT,5 EU/10100 µg
130427,DIAMETER,ALPRAZOLAM-TABLET-(KWALITY)-IP-12747,na,NULL,6.05 MM ±2%
130435,HARDNESS,ALPRAZOLAM-TABLET-(KWALITY)-IP-12747,alphanumeric,NLT,3.0 KG/CM²
130437,MICROBIAL LIMIT (TVC),ALPRAZOLAM-TABLET-(KWALITY)-IP-12747,alphanumeric,NMT,10°CFU/GM
130428,THICKNESS,ALPRAZOLAM-TABLET-(KWALITY)-IP-12747,na,NULL,3.30 MM ±2%
130803,AMIKACIN SULPHATE,AMIKACIN-SULPHATE-IP-12779,alphanumeric,674,786 µg(ON DRIED BASIS)
130796,<p>SPECIFIC OPTICAL ROTATION</p>,AMIKACIN-SULPHATE-IP-12779,alphanumeric,+76.0°, +84.0°
131129,HARDNESS,AMIODARONE-TABLET-(100-MG)-(KWALITY)-IP-12803,alphanumeric,NLT,4.0 KG/CM²
131147,HARDNESS,AMIODARONE-TABLET-(200-MG)-(KWALITY)-IP-12804,alphanumeric,NLT,4.0 KG/CM²
131149,MICROBIAL LIMIT (TVC),AMIODARONE-TABLET-(200-MG)-(KWALITY)-IP-12804,alphanumeric,NMT,10°CFU/GM
131161,HARDNESS,AMIODARONE-TABLET-(SAMARTH)-IP-12805,na,NULL,NLT 3.0 KG/CM²
131184,OPTICAL ROTATION,AMISULPRIDE-IP-12807,alphanumeric,-0.10°, +0.10°
58914,"Enterobacteriacae, cfu/ml",AMLA-CHATPATA-CANDY-FSSAI-5581,na,NULL,10°
58894,"Total Fungal count,cfu/ml",AMLA-CHATPATA-CANDY-FSSAI-5581,na,NULL,10°
58804,"Enterobacteriacae, cfu/ml",AMLA-JUICE-FSSAI-5573,na,NULL,Max. 10°
58768,"Total Fungal count,cfu/ml",AMLA-JUICE-FSSAI-5573,na,NULL,Max. 10°
59014,"Enterobacteriacae, cfu/ml",AMLA-KATTI-MEETHI-CANDY-FSSAI-5582,na,NULL,10°
59015,"Total Fungal count,cfu/ml",AMLA-KATTI-MEETHI-CANDY-FSSAI-5582,na,NULL,10°
59065,"Enterobacteriacae, cfu/ml",AMLA-MURABBA-FSSAI-5583,na,NULL,10°
59066,"Total Fungal count,cfu/ml",AMLA-MURABBA-FSSAI-5583,na,NULL,10°
131260,HARDNESS,AMLODINE-5-TABLET-(KWALITY)-GENERAL-12814,alphanumeric,NLT,3.0 KG/CM²
131259,MICROBIAL TEST (TVC),AMLODINE-5-TABLET-(KWALITY)-GENERAL-12814,alphanumeric,NMT,10°CFU/GM
131288,OPTICAL ROTATION,AMLODIPINE-BESYLATE-IP-12817,alphanumeric,-0.10°, +0.10°
131301,OPTICAL ROTATION,AMLODIPINE-BESYLATE-USP-12818,alphanumeric,-0.10°, +0.10°
131348,HARDNESS IN KG/CM²,AMLODIPINE-TABLET-(LA-CHEMICO)-IP-12823,na,NULL,NLT 2.0 KG/CM²
131350,<p>UNIFORMITY OF WEIGHT</p>,AMLODIPINE-TABLET-(LA-CHEMICO)-IP-12823,na,NULL,± 7.5%
131459,AVERAGE WEIGHT OF 20 CAPSULES,AMOXI-500-CAPSULE-(KWALITY)-BP-12834,na,NULL,691 MG ± 7.5%
131475,1-TOTAL AEROBIC MICROBIAL COUNT,AMOXI-500-ORAL-SUSPENSION-(KWALITY)-USP-12835,alphanumeric,NMT,10°CFU/GM
131476,2-TEST FOR SPECIFIED MICROORGANISMS,AMOXI-500-ORAL-SUSPENSION-(KWALITY)-USP-12835,alphanumeric,NMT,10°CFU/GM
131467,AVERAGE WEIGHT OF 5 CONTAINERS,AMOXI-500-ORAL-SUSPENSION-(KWALITY)-USP-12835,na,NULL,24.0 GM ± 10%
131511,AMOXICILLIN,AMOXICILLIN-TRIHYDRATE-USP-12838,alphanumeric,900, 1015 µg/mg (ON ANHYDROUS BASIS)
131603,AVERAGE WEIGHT OF 10 CONTAINERS,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-INJECTION-(KWALITY)-IP-12846,na,NULL,1.440 GM  ± 10%
131674,AVERAGE VOLUME OF 5 CONTAINERS,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-ORAL-SUSPENSION-(KWALITY)-IP-12852,na,NULL,3.3 GM  ±10%
131753,LENGTH,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-250+125)-IP-12859,na,NULL,17.20 MM ±0.2MM
131755,THICKNESS,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-250+125)-IP-12859,na,NULL,5.10 MM ±0.3 MM
131754,WIDTH,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-250+125)-IP-12859,na,NULL,8.60 MM ±0.2 MM
131769,LENGTH,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-500+125)-IP-12860,na,NULL,19.80 MM ±0.2MM
131771,THICKNESS,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-500+125)-IP-12860,na,NULL,6.25 MM ±0.3MM
131770,WIDTH,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-500+125)-IP-12860,na,NULL,9.30 MM ±0.2MM
131786,LENGTH,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-875+125)-IP-12861,na,NULL,21.50 MM ±0.2MM
131788,THICKNESS,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-875+125)-IP-12861,na,NULL,7.0 MM ±0.3 MM
131787,WIDTH,AMOXYCILLIN-&-POTASSIUM-CLAVULANATE-TABLET-(THEON-875+125)-IP-12861,na,NULL,10.50 MM ±0.2MM
131928,HARDNESS,AMOXYCILLIN-DISPERSIBLE-TABLET-(KWALITY)-IP-12874,alphanumeric,NLT,6.0 KG/CM²
131971,AVERAGE VOLUME OF 5 CONTAINERS,AMOXYCILLIN-ORAL-SUSPENSION-(KWALITY)-IP-12880,na,NULL,16.67 GM ± 10%
132017,<p>SPECIFIC OPTICAL ROTATION</p>,AMOXYCILLIN-SODIUM-(SARV)-IP-12884,alphanumeric,+240°, +290°
132027,<p>SPECIFIC OPTICAL ROTATION</p>,AMOXYCILLIN-SODIUM-INJECTION-IP-12885,alphanumeric,+240°, +290°
131991,<p>SPECIFIC OPTICAL ROTATION</p>,AMOXYCILLIN-SODIUM-IP-12882,alphanumeric,+240°, +290°
132067,<p>SPECIFIC OPTICAL ROTATION</p>,AMOXYCILLIN-TRIHYDRATE-BP-12888,alphanumeric,+290°, 315°
132052,<p>SPECIFIC OPTICAL ROTATION</p>,AMOXYCILLIN-TRIHYDRATE-IP-12887,alphanumeric,+290°, +315°
132084,UNIFORMITY WEIGHT OF CAPSULE CONTENT,AMPCLOX-CAPSULE-(KWALITY)-GENERAL-12890,alphanumeric,526.5, 643.5 MG (585 MG ± 10%)
132105,AVERAGE VOLUME OF 10 CONTAINERS,AMPICILLIN-&-CLOXACILLIN-INJECTION-(KWALITY)-GENERAL-12892,na,NULL,4.332 GM ± 10%
132177,<p>SPECIFIC OPTICAL ROTATION</p>,AMPICILLIN-INJECTION-(JACKSON)-IP-12897,alphanumeric,+258°, +287°
132191,AVERAGE WEIGHT OF 10 CONTAINERS,AMPICILLIN-INJECTION-(KWALITY)-IP-12898,na,NULL,536 MG ± 10%
132198,<p>SPECIFIC OPTICAL ROTATION</p>,AMPICILLIN-INJECTION-(KWALITY)-IP-12898,alphanumeric,+258°, +287°
132214,<p>SPECIFIC OPTICAL ROTATION</p>,AMPICILLIN-INJECTION-(MP)-IP-12899,alphanumeric,+258°, +287°
132235,<p>SPECIFIC OPTICAL ROTATION</p>,AMPICILLIN-INJECTION-(TAMIL)-IP-12900,alphanumeric,+258°, +287°
132159,<p>SPECIFIC OPTICAL ROTATION</p>,AMPICILLIN-INJECTION-IP-12896,alphanumeric,+258°, +287°
132263,<p>SPECIFIC OPTICAL ROTATION</p>,AMPICILLIN-SODIUM--STERILE-IP-12902,alphanumeric,+258°, +287°
132285,<p>SPECIFIC OPTICAL ROTATION</p>,AMPICILLIN-SODIUM-(GRAMPUS)-IP-12904,alphanumeric,+258°, +287°
132354,LENGTH,ANALGON-1500-BOLUS-GENERAL-12912,na,NULL,39.50 MM² 
132356,THICKNESS,ANALGON-1500-BOLUS-GENERAL-12912,na,NULL,7.8 MM ²
132355,WIDTH,ANALGON-1500-BOLUS-GENERAL-12912,na,NULL,13.0 MM ²
132585,<p>SPECIFIC OPTICAL ROTATION</p>,ARBUTIN-GENERAL-12934,alphanumeric,+171.0°, +186.0°
132680,<p>SPECIFIC OPTICAL ROTATION</p>,ARTEMETHER-IP-12945,alphanumeric,+166°, +173°
132701,<p>SPECIFIC OPTICAL ROTATION</p>,ARTESUNATE-IP-12946,alphanumeric,+4.5°, +6.5°
132760,<p>SPECIFIC OPTICAL ROTATION</p>,ASCORBIC-ACID-(VITAMIN-C)-IP-12952,alphanumeric,+20.5°, +21.5°
132739,<p>SPECIFIC OPTICAL ROTATION</p>,ASCORBIC-ACID-BP-12950,alphanumeric,+20.5°, +21.5°
132790,SPECIFIC ROTATION @25?C,ASCORBIC-ACID-ULTRAFINE-GENERAL-12956,alphanumeric,+20.5°, +21.5°
132880,CONDUCTIVITY,ASPARTAME-BP-12965,alphanumeric,NMT,NMT-30 µS-cm-¹
132864,<p>SPECIFIC OPTICAL ROTATION</p>,ASPARTAME-IP-12964,alphanumeric,+14.5°, +16.5°
132898,OPTICAL ROTATION,ASPARTAME-USP-12966,alphanumeric,+14.5°, +16.5°
132987,<p>AVERAGE WEIGHT</p>,ASPIRIN-TABLET-(KAWALITY)-IP-12975,na,NULL,110 MG ± 7.5%
132991,DISPERSION TEST,ASPIRIN-TABLET-(KAWALITY)-IP-12975,na,NULL,NO PARTICLE SHOULD BE OBSERVED AT MESH SIZE 710 ? (22 no.)
132993,HARDNESS,ASPIRIN-TABLET-(KAWALITY)-IP-12975,na,NULL,NLT 4.5 KG/CM²
132996,MICROBIAL LIMIT (TVC),ASPIRIN-TABLET-(KAWALITY)-IP-12975,na,NULL,NMT 10°CFU/GM
133561,MELTING POINT,AVOBENZONE/BMDM-GENERAL-13024,alphanumeric,81.0°C , 85°C
133679,SOFTENING (?C),AVON-MASTER-GENERAL-13026,alphanumeric,NLT,55°C
58555,Flash Point (Abel) [Cl.3.2.3],AZADIRACHTIN-0.03%-EC-FSSAI-5558,na,NULL,Above 24.5°C
58562,Flash Point (Abel) [Cl.3.2.3],AZADIRACHTIN-0.15%-EC-FSSAI-5559,na,NULL,Above 24.5°C
58569,Flash Point (Abel) [Cl.3.2.3],AZADIRACHTIN-1.0%-EC-FSSAI-5560,na,NULL,Above 24.5°C
64505,Flash Point (Abel) [Cl.3.2.3],AZADIRACHTIN-1500-PPM-(BIS)-NABL-6000,na,NULL,Above 24.5°C
133856,<p>PARTICLE SIZE</p>,AZITHROMYCIN-(HETERO)-GENERAL-13044,na,NULL,D(90)LESS THAN 20°C
133899,AZITHROMYCIN,AZITHROMYCIN-(MACLEOD-USP/IHS)-USP-13045,alphanumeric,945, 1030 µg/mg  (ON ANHYDROUS BASIS)
133931,AZITHROMYCIN,AZITHROMYCIN-DIHYDRATE-USP-13048,alphanumeric,945, 1030 µg/mg  (ON ANHYDROUS BASIS)
133820,<p>SPECIFIC OPTICAL ROTATION</p>,AZITHROMYCIN-IP-13042,alphanumeric,-45° , -49°
134031,HARDNESS IN KG/CM²,AZITHROMYCIN-TABELT-(LA-CHEMICO)-IP-13055,na,NULL,NLT 5.0 KG/CM²
134032,<p>UNIFORMITY OF WEIGHT</p>,AZITHROMYCIN-TABELT-(LA-CHEMICO)-IP-13055,na,NULL,±5% OF AVERAGE WT.
134083,BREADTH,AZITHROMYCIN-TABLET-(500-MG)-(KWALITY)-IP-13058,na,NULL,8.76 MM ±3%
134090,HARDNESS,AZITHROMYCIN-TABLET-(500-MG)-(KWALITY)-IP-13058,alphanumeric,NLT,NLT-8.0 KG/CM²
134084,HEIGHT,AZITHROMYCIN-TABLET-(500-MG)-(KWALITY)-IP-13058,na,NULL,6.14 MM ±3%
134082,LENGTH,AZITHROMYCIN-TABLET-(500-MG)-(KWALITY)-IP-13058,na,NULL,18.80 MM ±3%
134097,BREADTH,AZITHROMYCIN-TABLET-(KWALI)-USP-13059,na,NULL,7.35 MM ±3%
134105,HARDNESS,AZITHROMYCIN-TABLET-(KWALI)-USP-13059,na,NULL,NLT 2.0 KG/CM²
134098,HEIGHT,AZITHROMYCIN-TABLET-(KWALI)-USP-13059,na,NULL,7.60 MM ±3%
134096,LENGTH,AZITHROMYCIN-TABLET-(KWALI)-USP-13059,na,NULL,9.50 MM ±3%
134503,HARDNESS,BACLOFEN-TABLET-(SAMARTH)-IP-13102,alphanumeric,NLT,3.0 KG/CM²
134499,<p>UNIFORMITY OF WEIGHT VARIATION</p>,BACLOFEN-TABLET-(SAMARTH)-IP-13102,na,NULL,±7.5% OF AVG. WEIGHT
134550,A-FABRIC,"BANDAGE,-POP,-10CM²X-2.7-MT.-[5020][ESL]-BP-13107",alphanumeric,NLT,24 GM/M²
134551,B-BANDAGE,"BANDAGE,-POP,-10CM²X-2.7-MT.-[5020][ESL]-BP-13107",alphanumeric,NLT,340 GM/M²
134561,A-FABRIC,"BANDAGE,-POP,-15CM²X-2.7-MT.-[5021][ESL]-BP-13108",alphanumeric,NLT,24 GM/M²
134562,B-BANDAGE,"BANDAGE,-POP,-15CM²X-2.7-MT.-[5021][ESL]-BP-13108",alphanumeric,NLT,340 GM/M²
59484,<p>Agaric Acid (ppm)</p>,BARLEY-DALIA-FSSAI-5598,na,NULL,MAX. 10µg/Kg
59485,<p>Hydrocyanic Acid (ppm)</p>,BARLEY-DALIA-FSSAI-5598,na,NULL,MAX. 5.0 µg/Kg
59486,<p>Hypericine (ppm)</p>,BARLEY-DALIA-FSSAI-5598,na,NULL,MAX. 1.0 µg/Kg
59487,<p>Saffrole (ppm)</p>,BARLEY-DALIA-FSSAI-5598,na,NULL,MAX. 10.0 µg/Kg
134613,<p>SPECIFIC OPTICAL ROTATION</p>,BECLOMETHASONE-DIPROPIONATE-IP-13115,alphanumeric,88, +94.0°
134622,<p>SPECIFIC OPTICAL ROTATION</p>,BECLOMETHASONE-DIPROPIONATE-MONOHYDRATE-BP-13116,alphanumeric,+108°TO +115°,NULL
134725,MELTING POINT,BEESWAX-BLEACHED-GENERAL-13123,alphanumeric,62.0°C , 65.0°C
134719,MELTING POINT,BEESWAX-GENERAL-13122,alphanumeric,62.0°C , 65.0°C
134859,AVERAGE WEIGHT OF 10 CONTAINERS,BENZATHINE-PENICILLIN-INJECTION-(KWALITY)-IP-13138,na,NULL,506.7 ± 10%
134874,MELTING POINT,BENZETHONIUM-CHLORIDE-USP-13139,alphanumeric,158°, 163°
39755,Distillation range,BENZYL-ALCOHOL--NABL-4419,na,NULL,None Distills below 200?C and not less than 94% distills between 202?C adn 205?C
135036,DISTILLATION RANGE,BENZYL-ALCOHOL-(KABI)-IP-13155,na,NULL,NONE DISTILLS BELOW 200?C AND NOT LESS THAN 94% DISTILLS BETWEEN 202?C AND 205?C
135049,FREEZING POINT,BENZYL-BENZOATE-BP-13157,alphanumeric,NLT,17.0°
135040,CONGEALING TEMPERATURE,BENZYL-BENZOATE-IP-13156,alphanumeric,NLT,17°C
135059,CONGEALING TEMPERATURE,BENZYL-BENZOATE-USP-13158,alphanumeric,NLT,18.0°
135139,<p>SPECIFIC OPTICAL ROTATION</p>,BENZYL-PENICILLIN-SODIUM-STERILE-(OSPER)-IP-13167,alphanumeric,285°, +310°
135148,AVERAGE WEIGHT OF 10 CONTAINERS,BENZYLPENICILLIN-INJECTION-(KWALITY)-BP-13168,na,NULL,3.021 GM ± 10%
59431,<p>Agaric Acid (ppm)</p>,BESAN-FSSAI-5596,na,NULL,MAX. 10 µg/Kg
135262,<p>SPECIFIC OPTICAL ROTATION</p>,"BETADEX-(MACLEODS,-BOMBAY)-BP-13178",alphanumeric,+160.0°, +164.0°
135243,<p>SPECIFIC OPTICAL ROTATION</p>,BETADEX-BP-13177,alphanumeric,+160.0°, +164.0°
135308,HARDNESS,BETAHISTINE-TABLET-(ISHAANA)-IP-13181,alphanumeric,NLT,4.0 KG/CM²
135309,THICKNESS,BETAHISTINE-TABLET-(ISHAANA)-IP-13181,na,NULL,2.90 ± 0.2 MM
135340,<p>SPECIFIC OPTICAL ROTATION</p>,BETAMETHASONE-DIPROPIONATE-IP-13184,alphanumeric,+63.0°, +70.0°
135327,<p>SPECIFIC OPTICAL ROTATION</p>,BETAMETHASONE-IP-13183,alphanumeric,+114? , +122°
135385,<p>SPECIFIC OPTICAL ROTATION</p>,BETAMETHASONE-SODIUM-PHOSPHATE-IP-13189,alphanumeric,+98°, +104°
135532,FREEZING POINT,BHT-(BUTYLATED-HYDROXY-TOLUENE)-IP-13199,alphanumeric,69°, 70°
60205,Bifenthrin content (% by mass) [Cl.3.3(i)],BIFENTHRIN-10-%-WP(IS:15939-2011)-FSSAI-5669,na,NULL,10 ± 5% of the declared value
135682,<p>SPECIFIC OPTICAL ROTATION</p>,BIHAR-AMPICILLIN-INJECTION-IP-[DRUG-CODE-D0036]-IP-13215,alphanumeric,+258°, +287°
136052,2-CUFF,BIHAR-LATEX-SURGICAL-GLOVES-STERILE-7-1/2-INCH-[DRUG-CODE-S0046]-GENERAL-13245,na,NULL,5.0 mm ± 3.0 mm
136398,WEIGHT OF OINTMENT ON DRESSING IN GM,BIODONE-DRESSING-(10-CM²X-10-CM²-GENERAL-13277,na,NULL,3.0  ± 0.50 GM
136397,WEIGHT/UNIT AREA OF FABRIC,BIODONE-DRESSING-(10-CM²X-10-CM²-GENERAL-13277,alphanumeric,150, 210 G/M²
136418,<p>SPECIFIC OPTICAL ROTATION</p>,BIOTIN-(ARISTO)-BP-13280,alphanumeric,+89° TO+93°,NULL
136428,<p>SPECIFIC OPTICAL ROTATION</p>,BIOTIN-(CHARAK)-BP-13281,alphanumeric,+89° TO+93°,NULL
136448,<p>SPECIFIC OPTICAL ROTATION</p>,BIOTIN-PURE-(VOWCARE)-USP-13283,alphanumeric,+89° TO+93°,NULL
136439,<p>SPECIFIC OPTICAL ROTATION</p>,BIOTIN-PURE-USP-13282,alphanumeric,+89° TO+93°,NULL
136469,TOTAL ZINC,BIPHASIC-ISOPHANE-INSULIN-INJECTION-[1631][U]-IP-13285,na,NULL,NMT 40 µG/100 IU OF INSULIN
136539,<p>AVERAGE WEIGHT</p>,BISACODYL-TABLET-(KWALITY)-IP-13291,na,NULL,88 MG ± 7.5%
136550,HARDNESS,BISACODYL-TABLET-(KWALITY)-IP-13291,na,NULL,NLT 2.5 KG/CM²
136551,MICROBIAL LIMIT (TVC),BISACODYL-TABLET-(KWALITY)-IP-13291,na,NULL,NMT 10³ CFU/GM
136559,HARDNESS IN KG/CM²,BISACODYL-TABLET-(LA-CHEMICO)-IP-13292,na,NULL,NLT 4 KG/CM²
136586,<p>SPECIFIC OPTICAL ROTATION</p>,BISOPROLOL-FUMARATE-USP-13295,na,NULL,-2.0° TO +2.0°
136628,HARDNESS,BLACK-COHOSH-TABLET-(RICHFEEL)-GENERAL-13300,alphanumeric,NLT,2.0 KG/CM²
136730,<p>3-MASS GM/M2</p>,BLEACHED-GAUZE-CLOTH----(DRUG-CODE-R156)-GENERAL-13312,na,NULL,57 ± 5 GM/M²
136744,<p>3-MASS GM/M2</p>,BLEACHED-GAUZE-CLOTH----(DRUG-CODE-R157)-GENERAL-13313,na,NULL,57± 5 GM/M²
66356,<p>Flash Point (&deg;C)</p>,BLENDED-EDIBLE-VEGETABLE-OIL-NABL-6071,na,NULL,NLT 250°C
136908,LENGTH,BOLIN-NP-BOLUS-GENERAL-13327,na,NULL,39.50 MM ±0.02 MM
136910,THICKNESS,BOLIN-NP-BOLUS-GENERAL-13327,na,NULL,7.8 MM ±0.02 MM
136909,WIDTH,BOLIN-NP-BOLUS-GENERAL-13327,na,NULL,13.00 MM ±0.02 MM
137175,DIAMETER,BROMOCRIPTINE-MESYLATE-TABLET-(KWALITY)-IP-13352,na,NULL,8.11 MM ±3%
137187,MICROBIAL LIMITS,BROMOCRIPTINE-MESYLATE-TABLET-(KWALITY)-IP-13352,na,NULL,NMT 10³ CFU/GM
137176,THICKNESS,BROMOCRIPTINE-MESYLATE-TABLET-(KWALITY)-IP-13352,na,NULL,3.48 MM ±3%
62504,<p>Flash Point (Abel)</p>,BUTACHLOR-50%-EC-(IS:9356-1980)-FSSAI-5821,na,NULL,24.5°C
137536,FREEZING POINT,BUTYLATED-HYDROXY-TOLUENE-(SPB-LABS)-BP-13389,alphanumeric,69°C , 70°C
137514,FREEZING POINT,BUTYLATED-HYDROXY-TOLUENE-BP-13387,alphanumeric,69°C , 70°C
137981,<p>UNIFORMITY OF WEIGHT</p>,C31-DISPERSIBLE-TABLET-(ANGLO-FRENCHI)-GENERAL-13445,na,NULL,±5.0%W/W
138229,UNIFORMITY OF FILLED WEIGHT,C38+S75-INJECTION-(THEON)-GENERAL-13467,na,NULL,± 2% OF AVERAGE FILLED WEIGHT
139267,<p>SPECIFIC OPTICAL ROTATION</p>,CABERGOLINE-IP-13559,alphanumeric,-77.0°, -83.0°
139326,<p>IDENTIFICATION A</p>,CAFFEINE-ANHYDROUS-BP-13564,alphanumeric,234°C , 239°C
139550,ARSENIC,CALCIUM-ASCORBATE-USP-13581,alphanumeric,NMT,NMT-3.0 µg/gm
139553,OPTICAL ROTATION,CALCIUM-ASCORBATE-USP-13581,na,NULL,+95.0°+97.0°
139603,"-1,4-DIOXANE",CALCIUM-CARBONATE-(ARISTO)-USP-13585,na,NULL,NMT 380 µg/g
139602,CHLOROFORM,CALCIUM-CARBONATE-(ARISTO)-USP-13585,na,NULL,NMT 60µg/g
139605,TRICHLOROETHYLENE,CALCIUM-CARBONATE-(ARISTO)-USP-13585,na,NULL,NMT 80 µg/g
139601,BENZENE,CALCIUM-CARBONATE-(ARISTO)-USP-13585,na,NULL,NMT 2 µg/g
139604,<p>METHYLENE CHLORIDE</p>,CALCIUM-CARBONATE-(ARISTO)-USP-13585,na,NULL,NMT 600 µg/g
139730,<p>SPECIFIC OPTICAL ROTATION</p>,CALCIUM-D-PANTOTHENATE-IP-13597,alphanumeric,+ 25.0°, +27.5°
139881,"-1,4-DIOXANE",CALCIUM-STEARATE-(ARISTO)-USP-13613,alphanumeric,NMT,NMT 380 µg/g
139880,CHLOROFORM,CALCIUM-STEARATE-(ARISTO)-USP-13613,alphanumeric,NMT,NMT 60µg/g
139883,TRICHLOROETHYLENE,CALCIUM-STEARATE-(ARISTO)-USP-13613,alphanumeric,NMT,NMT 80 µg/g
139879,BENZENE,CALCIUM-STEARATE-(ARISTO)-USP-13613,alphanumeric,NMT,NMT 2 µg/g
139882,<p>METHYLENE CHLORIDE</p>,CALCIUM-STEARATE-(ARISTO)-USP-13613,alphanumeric,NMT,NMT 600 µg/g
140105,<p>SPECIFIC OPTICAL ROTATION</p>,CAPECITABINE-(RESIDUE)-GENERAL-13636,alphanumeric,+96.0°, +100.0°
140165,MELTING POINT,CAPRYLIC-CAPRIC-ISOST-AT-GENERAL-13642,alphanumeric,32.0°C , 37.0°C
140170,MELTING RANGE,CAPSAICIN-NATURAL-95%-USP-13643,alphanumeric,57° , 66°
140195,OPTICAL ROTATION,CAPTOPRIL-USP-13645,na,NULL,-125°TO -134°
140237,IDENTIFICATION B (PLASH POINT),CARAWAY-OIL-IP-13649,alphanumeric,54.0°, 58.0°
140240,OPTICAL ROTATION,CARAWAY-OIL-IP-13649,alphanumeric,+67.0°, +80.0°
140336,HARDNESS IN KG/CM²,CARBAMAZEPINE-TABLET-(LA-CHEMICO)-IP-13658,alphanumeric,NLT,5.0 KG/CM²
56471,<p>Carbendazim (MBC) Content (% by mass)</p>,CARBENDAZIM-12%-+-MANCOZEB-63%-WP-FSSAI-5380,na,NULL,12  ±5% of the nominal value
140415,HARDNESS,CARBIMAZOLE-TABLET-(KWALITY)-IP-13665,na,NULL,NLT 4.0 KG/CM²
140417,MICROBIAL LIMIT (TVC),CARBIMAZOLE-TABLET-(KWALITY)-IP-13665,na,NULL,NMT 10°CFU/GM
140432,FREEZING POINT,CARBOLIC-ACID-400-GM-(PHENOL)-[2399][U]-IP-13667,na,NULL,NLT 39.5?
140454,HEAVY METALS,CARBOMER-HOMOPOLYMER-TYPE-B-NF-CARBOPOL-974P-USP-13669,alphanumeric,NMT,20 µg/g
140458,LIMIT OF BENZENE,CARBOMER-HOMOPOLYMER-TYPE-B-NF-CARBOPOL-974P-USP-13669,alphanumeric,NMT,2.0 µg/g
140519,BENZENE,CARBOPOL-971-P-USP-13676,alphanumeric,NMT,2.0 µg/g
140608,OPTICAL ROTATION,CARDAMOM-OIL-IP-13685,alphanumeric,+22.0°, +44.0°
140744,OPTICAL ROTATION,CASTOR-OIL-BP-13696,alphanumeric,+3.5°, +6.0°
140732,OPTICAL ROTATION,CASTOR-OIL-IP-13695,alphanumeric,+3.5°, +6.0°
140900,<p>SPECIFIC OPTICAL ROTATION</p>,CEFADROXIL-IP-13713,alphanumeric,+165°, +178°
140951,AVERAGE WEIGHT OF 5 CONTAINERS,CEFADROXIL-ORAL-SUSPENSION-(KWALITY)-IP-13717,na,NULL,5.0 GM ± 10%
141024,<p>SPECIFIC OPTICAL ROTATION</p>,CEFAZOLIN-SODIUM-INJECTION-IP-13723,alphanumeric,-10°, -24°
140996,<p>SPECIFIC OPTICAL ROTATION</p>,CEFAZOLIN-SODIUM-IP-13721,alphanumeric,-10.0°, -24.0°
141067,CEFDINIR,CEFDINIR-GENERAL-13725,alphanumeric,940, 1030 µg/mg (ON ANHYDROUS BASIS)
141045,<p>SPECIFIC OPTICAL ROTATION</p>,CEFDINIR-GENERAL-13725,alphanumeric,-61.0°, -67.0°
141173,DIAMETER,CEFIXIME-DISPERSIBLE-TABLET-(THEON)-GENERAL-13737,na,NULL,9.60 MM ±0.2 MM
141174,THICKNESS,CEFIXIME-DISPERSIBLE-TABLET-(THEON)-GENERAL-13737,na,NULL,4.0°MM ±0.3 MM
141215,AVERAGE FILL WEIGHT,CEFIXIME-ORAL-SUSPENSION-(THEON)-IP-13743,na,NULL,15 GM ± 9%
141216,UNIFORMITY OF AVERAGE FILL WEIGHT,CEFIXIME-ORAL-SUSPENSION-(THEON)-IP-13743,na,NULL,± 9% OF AVERAGE FILL WEIGHT
141249,DIAMETER,CEFIXIME-TABLET-(KWALITY)-USP-13746,na,NULL,10.20 MM ±3%
141258,MICROBIAL TEST (TVC),CEFIXIME-TABLET-(KWALITY)-USP-13746,na,NULL,NMT 10°CFU/GM
141250,THICKNESS,CEFIXIME-TABLET-(KWALITY)-USP-13746,na,NULL,4.91 MM ±3%
141263,DIAMETER,CEFIXIME-TABLET-(THEON)-IP-13747,na,NULL,9.60 MM ±0.2 MM
141264,THICKNESS,CEFIXIME-TABLET-(THEON)-IP-13747,na,NULL,4.30 MM ±0.3 MM
141313,CEFIXIME TRIHYDRATE,CEFIXIME-TRIHYDRATE-USP-13750,alphanumeric,950, 1030 µg/mg (ON ANHDROUS BASIS)
141307,OPTICAL ROTATION,CEFIXIME-TRIHYDRATE-USP-13750,alphanumeric,-75°, -88°
141329,AVERAGE VOLUME OF 10 CONTAINERS,CEFOPERAZONE-&-SULBACTAM-FOR-INJECTION-(KWALITY)-GENERAL-13752,na,NULL,1.095 GM ± 10%
141473,AVERAGE FILLED WEIGHT,CEFOTAXIME-INJECTION-(THEON)-IP-13764,na,NULL,±2.0°OF TARGET FILLED  WEIGHT
141474,UNIFORMITY OF FILLED WEIGHT,CEFOTAXIME-INJECTION-(THEON)-IP-13764,na,NULL,±2.0°OF AVERAGE FILLED  WEIGHT
141594,AVERAGE FILLED WEIGHT,CEFOTAXIME-SODIUM-INJECTION-(THEON)-IP-13772,na,NULL,±2.0°OF TARGET FILLED  WEIGHT
141595,UNIFORMITY OF FILLED WEIGHT,CEFOTAXIME-SODIUM-INJECTION-(THEON)-IP-13772,na,NULL,±2.0°OF AVERAGE FILLED  WEIGHT
141722,CEFPODOXIME PROXETIL,CEFPODOXIME-PROXETIL-IP-13780,alphanumeric,690, 80°µG/MG(ON ANHYDROUS BASIS)
141718,<p>SPECIFIC OPTICAL ROTATION</p>,CEFPODOXIME-PROXETIL-IP-13780,alphanumeric,+35°, +48°
141834,LENGTH,CEFPODOXIME-PROXETIL-TABLET-(THEON)-IP-13790,na,NULL,16.10 MM±0.2MM
141835,THICKNESS,CEFPODOXIME-PROXETIL-TABLET-(THEON)-IP-13790,na,NULL,5.40MM ±0.3 MM
141836,WIDTH,CEFPODOXIME-PROXETIL-TABLET-(THEON)-IP-13790,na,NULL,7.60MM ±0.2 MM
141855,CEFPROZIL,CEFPROZIL-USP-13791,alphanumeric,900, 1050 µg/mg (ON ANHYDROUS BASIS)
141893,AVERAGE WEIGHT OF 10 CONTAINERS,CEFTAZIDIME-FOR-INJECTION-(KWALITY)-IP-13797,na,NULL,1264 MG ± 10%
142050,<p>SPECIFIC OPTICAL ROTATION</p>,CEFTIOFUR-SODIUM-IP-13810,alphanumeric,-60.0°, -70.0°
142083,AVERAGE WEIGHT OF 10 CONTAINERS,CEFTIOFUR-SODIUM-STERILE-POWDER-FOR-INJECTION-1G/VIAL-(KWALITY)-GENERAL-13814,na,NULL,1.055 GM ± 10%
142116,AVERAGE WEIGHT OF 10 CONTAINERS,CEFTIZOXIME-INJECTION-(KWALITY)-IP-13817,na,NULL,2.828 GM ± 10%
142131,CEFTIZOXIME SODIUM,CEFTIZOXIME-SODIUM-USP-13818,alphanumeric,850, 995 µg/mg (ON ANHYDROUS BASIS)
142245,UNIFORMITY OF FILLED WEIGHT,CEFTRIAXONE-INJECTION-1.0-GM-(THEON)-IP-13828,na,NULL,±2% OF AVG. FILLED WEIGHT
142292,CEFTRIAXONE SODIUM,CEFTRIAXONE-SODIUM-(MACLEODS)-USP-13831,alphanumeric,NLT,795 µg/mg (ON ANHYDROUS BASIS)
142305,<p>SPECIFIC OPTICAL ROTATION</p>,CEFTRIAXONE-SODIUM-(SARVE)-IP-13832,alphanumeric,-155.0°, -170.0°
142267,<p>SPECIFIC OPTICAL ROTATION</p>,CEFTRIAXONE-SODIUM-IP-13829,alphanumeric,-155.0°, -170.0°
142289,CEFTRIAXONE SODIUM,CEFTRIAXONE-SODIUM-USP-13830,alphanumeric,NLT,795 µg/mg (ON ANHYDROUS BASIS)
142357,<p>UNIFORMITY OF WEIGHT</p>,CEFUREX-250-TABLET-(RIDLEY)-IP-13836,na,NULL,± 5.0°OF AVG. WT.
142412,UNIFORMITY OF AVERAGE FILL,CEFUROXIME-AXETIL-FOR-ORAL-SUSPENSION-(THEON)-USP-13842,na,NULL,± 9% OF AVERAGE FILL WEIGHT
142467,HARDNESS,CEFUROXIME-AXETIL-TABLET-(KWALITY)-IP-13846,na,NULL,NLT 8.0 KG/CM²
142381,CEFUROXIME AXETIL,CEFUROXIME-AXETIL-USP-13838,alphanumeric,745, 875 µg/g (ON ANHYDROUS BASIS)
142514,<p>SPECIFIC OPTICAL ROTATION</p>,CEPHALEXIN-IP-13854,alphanumeric,+149°, +158?
142726,MELTING POINT (?C),CETODE-500-(ETHOXYLATE)-GENERAL-13875,alphanumeric,NLT,38.0°C
142736,SOLIDITYING POINT,CETOMACROGOL-1000-[CETODET-500]-BP-13876,alphanumeric,45°C , 53°C
142755,MELTING RANGE,CETOSTEARYL-ALCOHOL-(SPB-LABS)-IP-13878,alphanumeric,47°, 56°
142743,MELTING RANGE,CETOSTEARYL-ALCOHOL-IP-13877,alphanumeric,47°, 56°
142789,MELTING RANGE,CETYL-ALCOHOL-GENERAL-13883,alphanumeric,45.0?C , 50.0°C
142800,MELTING RANGE,CETYL-ALCOHOL-IP-13884,alphanumeric,46°, 52°
43025,<p>Agaric Acid (ppm)</p>,CHAKKI-ATTA-NABL-4627,na,NULL,MAX. 10 µg/Kg
43026,<p>Hydrocyanic Acid (ppm)</p>,CHAKKI-ATTA-NABL-4627,na,NULL,MAX. 5.0  µg/Kg
43027,<p>Hypericine (ppm)</p>,CHAKKI-ATTA-NABL-4627,na,NULL,MAX. 1.0  µg/Kg
43028,<p>Saffrole (ppm)</p>,CHAKKI-ATTA-NABL-4627,na,NULL,MAX. 10.0  µg/Kg
142899,<p>SPECIFIC OPTICAL ROTATION</p>,CHLORAMPHENICOL-CAPSULE-IP-13893,alphanumeric,+17.0°, +20.0°
142878,<p>SPECIFIC OPTICAL ROTATION</p>,CHLORAMPHENICOL-IP-13891,alphanumeric,+17.0°, +20.0°
143097,<p>IDENTIFICATION B</p>,CHLOROCRESOL-IP-13916,alphanumeric,85? , 88°
143149,BOILING RANGE,CHLOROFORM-(RS)-ARISTO-IP-13921,alphanumeric,NMT-5.0%V/V DISTILS BETWEEN 60°, 62°
143109,BOILING RANGE,CHLOROFORM-IP-13918,alphanumeric,NLT-95%V/V BLOW 60°, 62°
143240,OPTICAL ROTATION,CHLORPHENIRAMINE-MALEATE-BP-13932,alphanumeric,-0.10°, +0.10°
143227,IDENTIFICATION D,CHLORPHENIRAMINE-MALEATE-IP-13931,alphanumeric,+196°, +200°
66672,<p>Flash Point (Abel)</p>,CHLORPYRIFOS-50%-+-CYPERMETHRIN-5%-NABL-6094,na,NULL,24.5°C
143386,MELTING RANGE,CHLORZOXAZONE-(ARISTO)-USP-13946,alphanumeric,189°, 194°
143371,MELTING RANGE,CHLORZOXAZONE-USP-13945,alphanumeric,189°, 194°
143404,<p>SPECIFIC OPTICAL ROTATION</p>,CHOLECALCIFEROL-IP-13948,alphanumeric,+105°, +112°
143435,"-1,4-DIOXANE",CHOLINE-BITARTRATE-USP-13953,alphanumeric,NMT,10 µg/g
143437,METHANOL,CHOLINE-BITARTRATE-USP-13953,alphanumeric,NMT,300°µg/g
143436,ETHYLENE GLYCOL,CHOLINE-BITARTRATE-USP-13953,alphanumeric,NMT,620µg/g
143442,LIMIT OF TOTAL AMINE,CHOLINE-BITARTRATE-USP-13953,alphanumeric,NMT,10 µg/mg
143446,<p>SPECIFIC OPTICAL ROTATION</p>,CHOLINE-BITARTRATE-USP-13953,alphanumeric,+17.5° , 18.5°
143465,<p>SPECIFIC OPTICAL ROTATION</p>,CHONDROITIN-SULPHATE-SODIUM-USP-13955,alphanumeric,-20.0°, -30.0°
143610,<p>SPECIFIC OPTICAL ROTATION</p>,CICLESONIDE-IP-13970,alphanumeric,+90.0°, 98.0°
143654,MELTING POINT,CILNIDIPINE-GENERAL-13975,alphanumeric,108°, 113°C
143700,IDENTIFICATION B (PLASH POINT),CINNAMON-BARK-OIL-(DAALCHINI-KA-TEL)-IP-13981,alphanumeric,NLT,70.0°
143703,OPTICAL ROTATION,CINNAMON-BARK-OIL-(DAALCHINI-KA-TEL)-IP-13981,alphanumeric,-2.0°, +1.0°
143716,IDENTIFICATION B (PLASH POINT),CINNAMON-LEAF-OIL-IP-13982,alphanumeric,NLT,60.0°
143740,<p>IDENTIFICATION A</p>,CINNARIZINE-BP-13984,alphanumeric,118°C , 122°C
143847,HARDNESS,CIPROFLOXACIN-&-TINIDAZOLE-TABLET-(KWALITY)-GENERAL-13993,alphanumeric,NLT,8.0 KG/CM²
143848,MICROBIAL TEST (TVC),CIPROFLOXACIN-&-TINIDAZOLE-TABLET-(KWALITY)-GENERAL-13993,alphanumeric,NMT,10°CFU/GM
144024,HARDNESS,CIPROFLOXACIN-TABLET-(KWALITY)-IP-14009,na,NULL,NLT 8.0 KG/CM²
144027,MICROBIAL LIMIT (TVC),CIPROFLOXACIN-TABLET-(KWALITY)-IP-14009,na,NULL,NMT 10°CFU/GM
144032,BREADTH,CIPROFLOXACIN-TABLET-(KWALITY)-USP-14010,na,NULL,8.11 MM ±3%
144038,HARDNESS,CIPROFLOXACIN-TABLET-(KWALITY)-USP-14010,na,NULL,NLT 2.0 KG/CM²
144033,HEIGHT,CIPROFLOXACIN-TABLET-(KWALITY)-USP-14010,na,NULL,5.54 MM ±3%
144031,LENGTH,CIPROFLOXACIN-TABLET-(KWALITY)-USP-14010,na,NULL,16.5 MM ±3%
144201,OPTICAL ROTATION,CITRONELLA-OIL-BP-14028,alphanumeric,-4.0°, +1.5°
144222,<p>SPECIFIC OPTICAL ROTATION</p>,CLARITHROMYCIN-IP-14030,alphanumeric,-94°  , -102°
144263,HARDNESS,CLARITHROMYCIN-TABLET-(LA-CHEMICO)-IP-14033,alphanumeric,NLT,4.0 KG/CM²
144264,<p>UNIFORMITY OF WEIGHT</p>,CLARITHROMYCIN-TABLET-(LA-CHEMICO)-IP-14033,na,NULL,[± 5% OF AVERAGE WT.]
144237,HEAVY METALS,CLARITHROMYCIN-USP-14031,alphanumeric,NMT,20 µg/gm
144345,<p>SPECIFIC OPTICAL ROTATION</p>,CLINDAMYCIN-HYDROCHLORIDE-IP-14041,alphanumeric,+135°, +150°
144397,<p>SPECIFIC OPTICAL ROTATION</p>,CLINDAMYCIN-PHOSPHATE-IP-14045,alphanumeric,+115°, +130°
144425,CLINDAMYCIN PHOSPHATE,CLINDAMYCIN-PHOSPHATE-USP-14046,alphanumeric,NLT,758 µg/mg (ON ANHYDROUS BASIS)
144485,AVERAGE WEIGHT OF 5 CONTAINERS,CLOBETASOL-CREAM-(KWALITY)-BP-14054,na,NULL,15.0 GM ± 9%
144526,<p>SPECIFIC OPTICAL ROTATION</p>,CLOBETASOL-PROPIONATE-BP-14057,alphanumeric,+112°, +118°
144505,<p>SPECIFIC OPTICAL ROTATION</p>,CLOBETASOL-PROPIONATE-IP-14055,alphanumeric,+112°, +118°
144517,MELTING RANGE,CLOBETASOL-PROPIONATE-USP-14056,alphanumeric,ABOUT,196°
144518,OPTICAL ROTATION,CLOBETASOL-PROPIONATE-USP-14056,alphanumeric,+98°, +104°
55707,Clodinafop Propargyl content (% by mass),CLODINAFOP-PROPARGYL-15%-+-METSULFURON-METHYL-1%-WP-FSSAI-5317,na,NULL,15±5% of the declared value 
49410,Clodinafop Propargyl content (% by mass),CLODINAFOP-PROPARGYL-15%-WP-FSSAI-4955,na,NULL,15±5% of the nominal value
144887,AVERAGE WEIGHT OF 5 CONTAINERS,CLOTRIMAZOLE-CREAM-(KWALITY)-IP-14089,na,NULL,15.0 GM ± 9%
144980,<p>AVERAGE WEIGHT</p>,CLOTRIMAZOLE-VAGINAL-TABLET-(KWALITY)-IP-14099,na,NULL,1.0 GM ± 5%
144985,HARDNESS,CLOTRIMAZOLE-VAGINAL-TABLET-(KWALITY)-IP-14099,na,NULL,NLT 8.0 KG/CM²
43272,<p>Flash Point (&deg;C)</p>,CLOVE-BUD-OIL-IP--NABL-4635,na,NULL,110°C to 114°C
145460,"-1,4-DIOXANE",COLLOIDAL-SILICON-DIOXIDE-(ARISTO)-USP-14147,alphanumeric,NMT,380 µg/g
145459,CHLOROFORM,COLLOIDAL-SILICON-DIOXIDE-(ARISTO)-USP-14147,alphanumeric,NMT,60 µg/g
145462,TRICHLOROETHYLENE,COLLOIDAL-SILICON-DIOXIDE-(ARISTO)-USP-14147,alphanumeric,NMT,80 µg/g
145458,BENZENE,COLLOIDAL-SILICON-DIOXIDE-(ARISTO)-USP-14147,alphanumeric,NMT,2 µg/g
145461,<p>METHYLENE CHLORIDE</p>,COLLOIDAL-SILICON-DIOXIDE-(ARISTO)-USP-14147,alphanumeric,NMT,60 µg/g
145544,ARSENIC,COLOUR-IRON-OXIDE-RED-USNF-USP-14158,alphanumeric,NMT,3.0 µg/gm
145543,LEAD,COLOUR-IRON-OXIDE-RED-USNF-USP-14158,alphanumeric,NMT,3.0 µg/gm
145545,MERCURY,COLOUR-IRON-OXIDE-RED-USNF-USP-14158,alphanumeric,NMT,3.0 µg/gm
145550,LIMIT OF ARSENIC,COLOUR-IRON-OXIDE-YELLOW-USP-14159,alphanumeric,NMT,3 µg/g
145549,MERCURY,COLOUR-IRON-OXIDE-YELLOW-USP-14159,alphanumeric,NMT,3 µg/g
145867,LIMIT OF IRON,CORN-STARCH-USP-14190,alphanumeric,NMT,10 µg/g
145869,LIMIT OF SULFUR DIOXIDE,CORN-STARCH-USP-14190,alphanumeric,NMT,50 µg/g
146221,<p>1-BENZENE</p>,CROSS-CARMELLOSE-SODIUM-(ARISTO)-USP-14229,alphanumeric,NMT,NMT-2 µg/g
146222,2-CHLOROFORM,CROSS-CARMELLOSE-SODIUM-(ARISTO)-USP-14229,alphanumeric,NMT,60 µg/g
146223,"3-1,4-DIOXANE",CROSS-CARMELLOSE-SODIUM-(ARISTO)-USP-14229,alphanumeric,NMT,380 µg/g
146224,4-METHYLENE CHLORIDE,CROSS-CARMELLOSE-SODIUM-(ARISTO)-USP-14229,alphanumeric,NMT,NMT-600 µg/g
146225,5-TRICHLOROETHYLENE,CROSS-CARMELLOSE-SODIUM-(ARISTO)-USP-14229,alphanumeric,NMT,NMT-80 µg/g
146237,<p>1-BENZENE</p>,CROSS-CARMELLOSE-SODIUM-(KABI)-USP-14230,alphanumeric,NMT,NMT-2 µg/g
146238,2-CHLOROFORM,CROSS-CARMELLOSE-SODIUM-(KABI)-USP-14230,alphanumeric,NMT,60 µg/g
146239,"3-1,4-DIOXANE",CROSS-CARMELLOSE-SODIUM-(KABI)-USP-14230,alphanumeric,NMT,380 µg/g
146240,4-METHYLENE CHLORIDE,CROSS-CARMELLOSE-SODIUM-(KABI)-USP-14230,alphanumeric,NMT,NMT-600 µg/g
146241,5-TRICHLOROETHYLENE,CROSS-CARMELLOSE-SODIUM-(KABI)-USP-14230,alphanumeric,NMT,NMT-80 µg/g
146202,<p>1-BENZENE</p>,CROSS-CARMELLOSE-SODIUM-USP-14228,alphanumeric,NMT,NMT-2 µg/g
146203,2-CHLOROFORM,CROSS-CARMELLOSE-SODIUM-USP-14228,alphanumeric,NMT,60 µg/g
146204,"3-1,4-DIOXANE",CROSS-CARMELLOSE-SODIUM-USP-14228,alphanumeric,NMT,380 µg/g
146205,4-METHYLENE CHLORIDE,CROSS-CARMELLOSE-SODIUM-USP-14228,alphanumeric,NMT,NMT-600 µg/g
146206,5-TRICHLOROETHYLENE,CROSS-CARMELLOSE-SODIUM-USP-14228,alphanumeric,NMT,NMT-80 µg/g
44531,Cyfluthrin Content (% by mass),CYFLUTHRIN-10%-WP-(IS:14158-1994)-NABL-4698,na,NULL,NMT-2 µg/g
61666,<p>Flash Point (Abel)</p>,CYPHENOTHRIN-5%-EC-FSSAI-5741,na,NULL,24.5°C
146507,<p>SPECIFIC OPTICAL ROTATION</p>,CYPROTERONE-ACETATE-IP-14257,na,NULL, +157°
147454,IDENTIFICATION- B (OPTICAL ROTATION) (D ISOMER),D-ALPHA-TOCOPHEROL-(VITAMIN-E)-USP-14351,alphanumeric,NLT, +24°
150166,<p>SPECIFIC OPTICAL ROTATION</p>,D-PANTHENOL-(SPB-LABS)-IP-14613,na,NULL,28.2° TO +30.2°
150176,<p>SPECIFIC OPTICAL ROTATION</p>,D-PANTHENOL-(VOWCARE)-IP-14614,na,NULL,28.2° TO +30.2°
150144,<p>SPECIFIC OPTICAL ROTATION</p>,D-PANTHENOL-IP-14611,na,NULL,28.2° TO +30.2°
150156,MELTING RANGE,D-PANTHENOL-USP-14612,na,NULL,64.5° to 68.5°
150157,OPTICAL ROTATION,D-PANTHENOL-USP-14612,alphanumeric,-0.05°, +0.05°
146544,CONDUCTIVITY,D.M.-WATER-(BAN-LAB)-IP-14261,na,NULL,MAX. 5.0 µs/cm
147533,<p>SPECIFIC OPTICAL ROTATION</p>,DEFLAZACORT-GENERAL-14363,alphanumeric,+150°, +165°
147548,DIMENSION,DEFLAZACORT-TABLET-(THEON)-GENERAL-14365,na,NULL,8.00 MM ±2 MM
147555,HARDNESS,DEFLAZACORT-TABLET-(THEON)-GENERAL-14365,alphanumeric,NLT,NLT-3.0 KG/CM²
147549,THICKNESS,DEFLAZACORT-TABLET-(THEON)-GENERAL-14365,na,NULL,3.50 MM ±0.3 MM
147665,LIMIT OF ANTIMONY,DESFLURANE-[2078][AML]-USP-14376,na,NULL,NMT 3 µg/gM
147688,<p>SPECIFIC OPTICAL ROTATION</p>,DESOGESTREL-BP-14378,na,NULL,+53° TO +57°
147753,<p>SPECIFIC OPTICAL ROTATION</p>,DEXAMETHASONE-IP-14384,alphanumeric,+75.0°, +80.0°
147791,<p>SPECIFIC OPTICAL ROTATION</p>,DEXAMETHASONE-SODIUM-PHOSPHATE-IP-14387,alphanumeric,+75.0°, +83.0°
147867,<p>SPECIFIC OPTICAL ROTATION</p>,DEXCHLORPHENIRAMINE-MALEATE-BP-14393,alphanumeric,+22.0°, +25.0°
147855,<p>SPECIFIC OPTICAL ROTATION</p>,DEXCHLORPHENIRAMINE-MALEATE-IP-14392,alphanumeric,+22.0°, +23.0°
147975,<p>SPECIFIC OPTICAL ROTATION</p>,DEXTROMETHORPHAN-HYDROBROMIDE-IP-14401,alphanumeric,+28.0°, +30.0°
148119,<p>AVERAGE WEIGHT</p>,"DIAREX-VET-BOLUS-(HIMALAYA,-BANGALORE)-GENERAL-14414",na,NULL,6 G ± 2%
148121,HARDNESS,"DIAREX-VET-BOLUS-(HIMALAYA,-BANGALORE)-GENERAL-14414",alphanumeric,NLT,10.0 KG/CM²
148250,ARSENIC,DIBASIC-CALCIUM-PHOSPHATE-DIHYDRATE-USP-14425,alphanumeric,NLT,3.0 µg/g
55722,<p>Flash Point (Abel)</p>,DICHLORVOS-76%-EC-(IS:-5277-1978)-FSSAI-5320,na,NULL,Above 24.5°C
148397,AVERAGE VOLUME OF 5 CONTAINERS,DICLOFENAC-GEL-(KWALITY)-BP-14437,na,NULL,15.0 GM ± 9%
148405,MICROBIAL TEST (TVC),DICLOFENAC-GEL-(KWALITY)-BP-14437,alphanumeric,NMT,10°CFU/GM
148617,<p>SPECIFIC OPTICAL ROTATION</p>,DICLOXACILLIN-SODIUM-IP-14457,alphanumeric,+128°, + 143°
148664,HARDNESS,DICYCLOMINE-HCL.-TABLET-(KWALITY)-IP-14462,na,NULL,NLT 3.0 KG/CM²
148668,MICROBIAL LIMIT (TVC),DICYCLOMINE-HCL.-TABLET-(KWALITY)-IP-14462,na,NULL,NMT 10°CFU/GM
148736,MICROBIAL LIMITS,DICYCLOMINE-ORAL-SUSPENSION-(KWALITY)-GENERAL-14469,na,NULL,NMT 10°CFU/GM
148752,VISCOSITY,DIETHANOL-AMINE-LAURYL-SULPHATE-(D.E.L.S.)-GENERAL-14471,alphanumeric,VISCOSITY AT 25°C BY MULTIPLYING READING BY 10°, GET VISCOSITY IN CPS
148820,HARDNESS IN KG/CM²,DIETHYLCARBAMAZINE-TABLET-(LA-CHEMICO)-IP-14478,na,NULL,NLT 3.0 KG/CM²
148849,MELTING POINT,DIETHYLSTILBESTROL-GENERAL-14481,alphanumeric,169°, 172°C
41037,Diflubenzuron content (% by mass),DIFLUBENZURON-25%-WP-(IS:14186:1994)-NABL-4518,na,NULL,25±5% of the nominal value 
148872,<p>SPECIFIC OPTICAL ROTATION</p>,DIGOXIN-IP-14484,alphanumeric,+10.0°, +13.0°
148902,HARDNESS,DIGOXIN-TABLET-(SAMAR)-IP-14486,alphanumeric,NLT,3.0 KG/CM²
148914,HARDNESS,DIGOXIN-TABLET-(SAMARTH)-IP-14487,alphanumeric,NLT,3.0 KG/CM²
148947,DIAMETER,DILTIAZEM-HCL.-TABLET-(KWALITY)-USP-14491,na,NULL,8.0°MM ±3%
148959,MICROBIAL TEST (TVC),DILTIAZEM-HCL.-TABLET-(KWALITY)-USP-14491,na,NULL,NMT 10°CFU/GM
148948,THICKNESS,DILTIAZEM-HCL.-TABLET-(KWALITY)-USP-14491,na,NULL,3.83 MM ±3%
148992,<p>IDENTIFICATION A</p>,DIMENHYDRINATE-BP-14496,alphanumeric,102°, 106°
56473,Boiling Point ,DIMETHYLACETAMIDE--NABL-5381,na,NULL,About 165°C
149054,BOILING POINT,DIMETHYLACETAMIDE-(KABI)-GENERAL-14504,alphanumeric,ABOUT,165°C
149319,CONDUCTIVITY,DISTILLED-WATER-IP-14533,alphanumeric,NLT,4.0 µmhos/cm
149463,OPTICAL ROTATION,DOBUTAMINE-HYDROCHLORIDE-IP-14547,alphanumeric,-0.05°, +0.05°
149767,HARDNESS,"DOMPERIDONE-TABLET-(ADROIT,-NAGPUR)-IP-14576",alphanumeric,2, 6.000°KG/CM²
149796,HARDNESS IN KG/CM²,DOMPERIDONE-TABLET-(LA-CHEMICO)-IP-14578,alphanumeric,NLT,4.0 KG/CM²
149886,HEAVY METALS,DOSHION-P544D(POLACRILLIN-POTASSIUM-USP)-USP-14587,alphanumeric,NMT,20 µg/g
150073,<p>SPECIFIC OPTICAL ROTATION</p>,DOXYCYCLINE-HYDROCHLORIDE-IP-14605,alphanumeric,-105°, -120°
150130,DOXYCYCLINE MONOHYDRATE,DOXYCYCLINE-MONOHYDRATE-USP-14609,alphanumeric,880, 980 µg/mg (ON ANHYDROUS BASIS)
150246,<p>AVERAGE WEIGHT</p>,"DROSPIRENONE-&-ETHINYLOESTRADIOL-TABLET-(ACCENT-PHARMA,-SOLAN)-GENERAL-14621",na,NULL,80.0 MG ± 2%
150249,HARDNESS,"DROSPIRENONE-&-ETHINYLOESTRADIOL-TABLET-(ACCENT-PHARMA,-SOLAN)-GENERAL-14621",na,NULL,NLT 3.0 KG/CM²
150248,THICKNESS,"DROSPIRENONE-&-ETHINYLOESTRADIOL-TABLET-(ACCENT-PHARMA,-SOLAN)-GENERAL-14621",na,NULL,2.8 ± 0.2 MM
150247,<p>UNIFORMITY OF WEIGHT</p>,"DROSPIRENONE-&-ETHINYLOESTRADIOL-TABLET-(ACCENT-PHARMA,-SOLAN)-GENERAL-14621",na,NULL,± 7.5% OF AVERAGE WEIGHT
197694,<p>AVERAGE WEIGHT</p>,DROSPIRENONE-&-ETHINYLOESTRADIOL-TABLET-(ACCENT-PHARMA)-USP-18900,na,NULL,80.0 MG ± 2%
197695,<p>UNIFORMITY OF WEIGHT</p>,DROSPIRENONE-&-ETHINYLOESTRADIOL-TABLET-(ACCENT-PHARMA)-USP-18900,na,NULL,± 7.5% OF AVERAGE WEIGHT
150257,MELTING POINT,DROTAVERINE-HYDROCHLORIDE-GENERAL-14622,alphanumeric,205, 215°C
150337,HARDNESS,DURON-100-TABLET-(SAMARTH)-IP-14632,alphanumeric,NLT,3.0 KG/CM²
150349,HARDNESS,DURON-200-TABLET-(SAMARTH)-IP-14633,alphanumeric,NLT,3.0 KG/CM²
150906,WEIGHT OF ADHESIVE MASS,ELASTIC-ADHESIVE-BANDAGE-BP-[10490][ASL]-BP-14692,alphanumeric,[NLT,120 GM/M²]
150913,WEIGHT PER UNIT AREA,ELASTIC-ADHESIVE-BANDAGE-BP-[10490][ASL]-BP-14692,alphanumeric,NLT,130 GM/M²
150919,WEIGHT OF ADHESIVE MASS,ELASTIC-ADHESIVE-BANDAGE-BP-8-CM²X-4/P-[10430][ASL]-BP-14693,alphanumeric,[NLT,120 GM/M²]
150926,WEIGHT PER UNIT AREA,ELASTIC-ADHESIVE-BANDAGE-BP-8-CM²X-4/P-[10430][ASL]-BP-14693,alphanumeric,NLT,130 GM/M²
150936,WEFT,ELASTIC-CREPE-BANDAGE-4-INCH-[10231][ESL]-BP-14694,alphanumeric,NLT,140 GM/M²
41411,<p>Uniformity of weight (gm)</p>,ELNEURO-FORTE-CAPSSULE-NABL-4538,na,NULL,±5% of avg. wt
151064,<p>SPECIFIC OPTICAL ROTATION</p>,EMTRICITABINE-(HETERO)-IP-14706,alphanumeric,-125°, -150°
151126,<p>SPECIFIC OPTICAL ROTATION</p>,ENALAPRIL-MALEATE-IP-14711,alphanumeric,-41.0°, -43.5°
151145,OPTICAL ROTATION,ENALAPRIL-MALEATE-USP-14712,alphanumeric,-41.0°, 43.5°
151205,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-9.5-MM-[10208][ESL]-GENERAL-14719,na,NULL,MIN. 56 KGF/cm²
151211,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-9.5-MM-[10208][ESL]-GENERAL-14719,na,NULL,76 ± 4 IRHD
151199,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-9.5-MM-[10208][ESL]-GENERAL-14719,na,NULL,MIN. 56 KGF/CM²
151212,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-9.5-MM-[10208][ESL]-GENERAL-14719,na,NULL,81±  4 IRHD
151206,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-9.5-MM-[10208][ESL]-GENERAL-14719,na,NULL,MIN. 84 KGF/CM²
151200,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-9.5-MM-[10208][ESL]-GENERAL-14719,na,NULL,MIN. 39.2 KGF/CM²
151197,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-9.5-MM-[10208][ESL]-GENERAL-14719,na,NULL,1.2 MM ±0.2 MM
151227,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-CUFF-5-MM-[5529][ESL]-GENERAL-14720,na,NULL,76 ± 4 IRHD
151219,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-CUFF-5-MM-[5529][ESL]-GENERAL-14720,na,NULL,MIN. 56 KGF/CM²
151228,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-CUFF-5-MM-[5529][ESL]-GENERAL-14720,na,NULL,81 ± 4 IRHD
151220,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-CUFF-5-MM-[5529][ESL]-GENERAL-14720,na,NULL,MIN. 39.2 KGF/CM²
151217,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-CUFF-5-MM-[5529][ESL]-GENERAL-14720,na,NULL,1.2 MM ±0.2 MM
151245,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-4-MM-[10365][ESL]-GENERAL-14721,na,NULL,86 ± 4 IRHD
151239,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-4-MM-[10365][ESL]-GENERAL-14721,na,NULL,MIN. 56 KGF/CM²
151246,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-4-MM-[10365][ESL]-GENERAL-14721,na,NULL,89 ± 4 IRHD
151240,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-4-MM-[10365][ESL]-GENERAL-14721,na,NULL,MIN. 39.2 KGF/CM²
151237,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-4-MM-[10365][ESL]-GENERAL-14721,na,NULL,0.6 MM ±0.1 MM
151265,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-4.5-MM-[10364][ESL]-GENERAL-14722,na,NULL,MIN. 105 KGF/cm²
151261,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-4.5-MM-[10364][ESL]-GENERAL-14722,na,NULL,86 ± 4 IRHD
151255,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-4.5-MM-[10364][ESL]-GENERAL-14722,na,NULL,MIN. 56 KGF/CM²
151262,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-4.5-MM-[10364][ESL]-GENERAL-14722,na,NULL,89 ± 4 IRHD
151256,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-4.5-MM-[10364][ESL]-GENERAL-14722,na,NULL,MIN. 39.2 KGF/CM²
151253,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-4.5-MM-[10364][ESL]-GENERAL-14722,na,NULL,0.6 MM ±0.1 MM
151299,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-5-MM-CUFFED-[10366][ESL]-GENERAL-14724,na,NULL,MIN. 105 KGF/cm²
151295,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-5-MM-CUFFED-[10366][ESL]-GENERAL-14724,na,NULL,86 ± 4 IRHD
151289,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-5-MM-CUFFED-[10366][ESL]-GENERAL-14724,na,NULL,MIN. 56 KGF/CM²
151296,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-5-MM-CUFFED-[10366][ESL]-GENERAL-14724,na,NULL,89 ± 4 IRHD
151290,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-5-MM-CUFFED-[10366][ESL]-GENERAL-14724,na,NULL,MIN. 39.2 KGF/CM²
151287,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-5-MM-CUFFED-[10366][ESL]-GENERAL-14724,na,NULL,1.0 MM ±0.1 MM
151280,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-5-MM-GENERAL-14723,na,NULL,86 ± 4 IRHD
151274,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-5-MM-GENERAL-14723,na,NULL,MIN. 56 KGF/CM²
151281,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-5-MM-GENERAL-14723,na,NULL,89 ± 4 IRHD
151275,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-5-MM-GENERAL-14723,na,NULL,MIN. 39.2 KGF/CM²
151272,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-5-MM-GENERAL-14723,na,NULL,1.0 MM ±0.1 MM
151314,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-5.5-MM-GENERAL-14725,na,NULL,MIN. 105 KGF/cm²
151320,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-5.5-MM-GENERAL-14725,na,NULL,76 ± 4 IRHD
151308,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-5.5-MM-GENERAL-14725,na,NULL,MIN. 56 KGF/CM²
151321,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-5.5-MM-GENERAL-14725,na,NULL,81 ± 4 IRHD
151315,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-5.5-MM-GENERAL-14725,na,NULL,MIN. 84 KGF/CM²
151309,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-5.5-MM-GENERAL-14725,na,NULL,MIN. 39.2 KGF/CM²
151306,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-5.5-MM-GENERAL-14725,na,NULL,1.2 MM ±0.2 MM
151335,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-6-MM-GENERAL-14726,na,NULL,MIN. 105 KGF/cm²
151341,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-6-MM-GENERAL-14726,na,NULL,76 ± 4 IRHD
151329,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-6-MM-GENERAL-14726,na,NULL,MIN. 56 KGF/CM²
151342,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-6-MM-GENERAL-14726,na,NULL,81 ± 4 IRHD
151336,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-6-MM-GENERAL-14726,na,NULL,MIN. 84 KGF/CM²
151330,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-6-MM-GENERAL-14726,na,NULL,MIN. 39.2 KGF/CM²
151327,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-6-MM-GENERAL-14726,na,NULL,1.2 MM ±0.2 MM
151356,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-6.5-MM-GENERAL-14727,na,NULL,MIN. 105 KGF/cm²
151362,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-6.5-MM-GENERAL-14727,na,NULL,76 ± 4 IRHD
151350,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-6.5-MM-GENERAL-14727,na,NULL,MIN. 56 KGF/CM²
151363,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-6.5-MM-GENERAL-14727,na,NULL,81± 4 IRHD
151357,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-6.5-MM-GENERAL-14727,na,NULL,MIN. 84 KGF/CM²
151351,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-6.5-MM-GENERAL-14727,na,NULL,MIN. 39.2 KGF/CM²
151348,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-6.5-MM-GENERAL-14727,na,NULL,1.2 MM ±0.2 MM
151373,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-7-MM-GENERAL-14729,na,NULL,MIN. 56 KGF/CM²
151380,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-7-MM-GENERAL-14729,na,NULL,MIN. 84 KGF/CM²
151374,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-7-MM-GENERAL-14729,na,NULL,MIN. 39.2 KGF/CM²
151371,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-7-MM-GENERAL-14729,na,NULL,1.2 MM  ± 0.2 MM
151400,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-7.5-MM-GENERAL-14730,na,NULL,MIN. 105 KGF/cm²
151406,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-7.5-MM-GENERAL-14730,na,NULL,76 ± 4 IRHD
151394,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-7.5-MM-GENERAL-14730,na,NULL,MIN. 56 KGF/CM²
151407,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-7.5-MM-GENERAL-14730,na,NULL,81 ± 4 IRHD
151401,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-7.5-MM-GENERAL-14730,na,NULL,MIN. 84 KGF/CM²
151395,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-7.5-MM-GENERAL-14730,na,NULL,MIN. 39.2 KGF/CM²
151392,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-7.5-MM-GENERAL-14730,na,NULL,1.0 MM± 0.1 MM
151421,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-8-MM-GENERAL-14731,na,NULL,MIN. 105 KGF/cm²
151427,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-8-MM-GENERAL-14731,na,NULL,76 ± 4 IRHD
151415,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-8-MM-GENERAL-14731,na,NULL,MIN. 56 KGF/CM²
151428,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-8-MM-GENERAL-14731,na,NULL,81 ± 4 IRHD
151422,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-8-MM-GENERAL-14731,na,NULL,MIN. 84 KGF/CM²
151416,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-8-MM-GENERAL-14731,na,NULL,MIN. 39.2 KGF/CM²
151413,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-8-MM-GENERAL-14731,na,NULL,1.0 MM ±0.1 MM
151442,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-8.5-MM-GENERAL-14732,na,NULL,MIN. 105 KGF/cm²
151448,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-8.5-MM-GENERAL-14732,na,NULL,76 ± 4 IRHD
151436,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-8.5-MM-GENERAL-14732,na,NULL,MIN. 56 KGF/CM²
151449,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-8.5-MM-GENERAL-14732,na,NULL,81 ± 4 IRHD
151443,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-8.5-MM-GENERAL-14732,na,NULL,MIN. 84 KGF/CM²
151437,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-8.5-MM-GENERAL-14732,na,NULL,MIN. 39.2 KGF/CM²
151434,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-8.5-MM-GENERAL-14732,na,NULL,1.2 MM ±0.2 MM
151463,A-BEFORE    AGEING,ENDOTRACHEAL-TUBE-DIA-9-MM-[5533][ESL]-GENERAL-14733,na,NULL,MIN. 105 KGF/cm²
151469,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-DIA-9-MM-[5533][ESL]-GENERAL-14733,na,NULL,76 ± 4 IRHD
151457,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-DIA-9-MM-[5533][ESL]-GENERAL-14733,na,NULL,MIN. 56 KGF/CM²
151470,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-DIA-9-MM-[5533][ESL]-GENERAL-14733,na,NULL,81 ± 4 IRHD
151464,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-9-MM-[5533][ESL]-GENERAL-14733,na,NULL,MIN. 84 KGF/CM²
151458,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-DIA-9-MM-[5533][ESL]-GENERAL-14733,na,NULL,MIN. 39.2 KGF/CM²
151455,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-DIA-9-MM-[5533][ESL]-GENERAL-14733,na,NULL,1.6 MM ±0.2 MM
151484,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-5.5-MM-[10367][ESL]-GENERAL-14734,na,NULL,76 ± 4 IRHD
151478,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-5.5-MM-[10367][ESL]-GENERAL-14734,na,NULL,MIN. 56 KGF/CM²
151485,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-UNCUFFED-5.5-MM-[10367][ESL]-GENERAL-14734,na,NULL,81 ± 4 IRHD
151479,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-5.5-MM-[10367][ESL]-GENERAL-14734,na,NULL,MIN. 39.2 KGF/CM²
151476,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-5.5-MM-[10367][ESL]-GENERAL-14734,na,NULL,1.2 MM ± 0.2 MM
151499,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2-MM-[10209][ESL]-GENERAL-14735,na,NULL,84 ± 4 IRHD
151493,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2-MM-[10209][ESL]-GENERAL-14735,na,NULL,MIN. 56 KGF/CM²
151500,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2-MM-[10209][ESL]-GENERAL-14735,na,NULL,89 ± 4 IRHD
151494,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2-MM-[10209][ESL]-GENERAL-14735,na,NULL,MIN. 39.2 KGF/CM²
151491,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2-MM-[10209][ESL]-GENERAL-14735,na,NULL,0.6 MM ±0.1 MM
151514,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2.5-MM-GENERAL-14736,na,NULL,86 ± 4 IRHD
151508,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2.5-MM-GENERAL-14736,na,NULL,MIN. 56 KGF/CM²
151515,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2.5-MM-GENERAL-14736,na,NULL,89 ± 4 IRHD
151509,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2.5-MM-GENERAL-14736,na,NULL,MIN. 39.2 KGF/CM²
151506,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-2.5-MM-GENERAL-14736,na,NULL,0.6 MM ±0.1 MM
151529,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3-MM-GENERAL-14737,na,NULL,86 ± 4 IRHD
151523,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3-MM-GENERAL-14737,na,NULL,MIN. 56 KGF/CM²
151530,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3-MM-GENERAL-14737,na,NULL,89 ± 4 IRHD
151524,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3-MM-GENERAL-14737,na,NULL,MIN. 39.2 KGF/CM²
151521,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3-MM-GENERAL-14737,na,NULL,0.1 MM ±0.2 MM
151544,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3.5-MM-GENERAL-14738,na,NULL,86 ± 4 IRHD
151538,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3.5-MM-GENERAL-14738,na,NULL,MIN. 56 KGF/CM²
151545,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3.5-MM-GENERAL-14738,na,NULL,89 ± 4 IRHD
151539,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-3.5-MM-GENERAL-14738,na,NULL,MIN. 39.2 KGF/CM²
151559,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4-MM-GENERAL-14739,na,NULL,86 ± 4 IRHD
151553,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4-MM-GENERAL-14739,na,NULL,MIN. 56 KGF/CM²
151560,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4-MM-GENERAL-14739,na,NULL,89 ± 4 IRHD
151554,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4-MM-GENERAL-14739,na,NULL,MIN. 39.2 KGF/CM²
151551,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4-MM-GENERAL-14739,na,NULL,0.6 MM ±0.1 MM
151574,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4.5-MM-GENERAL-14740,na,NULL,86 ± 4 IRHD
151568,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4.5-MM-GENERAL-14740,na,NULL,MIN. 56 KGF/CM²
151575,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4.5-MM-GENERAL-14740,na,NULL,89 ± 4 IRHD
151569,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4.5-MM-GENERAL-14740,na,NULL,MIN. 39.2 KGF/CM²
151566,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-4.5-MM-GENERAL-14740,na,NULL,0.6 MM ±0.1 MM
151589,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-5-MM-[10214][ESL]-GENERAL-14741,na,NULL,86 ± 4 IRHD
151583,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-5-MM-[10214][ESL]-GENERAL-14741,na,NULL,MIN. 56 KGF/CM²
151590,<p>B-AFTER ACCELERATED AGEING AT 70&deg; &plusmn; 1&deg;C FOR 168 HOURS</p>,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-5-MM-[10214][ESL]-GENERAL-14741,na,NULL,89 ± 4 IRHD
151584,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-5-MM-[10214][ESL]-GENERAL-14741,na,NULL,MIN. 39.2 KGF/CM²
151581,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-5-MM-[10214][ESL]-GENERAL-14741,na,NULL,1.0 MM ±0.1 MM
151604,A-BEFORE   AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-DIA-2-MM-[10209][ESL]-GENERAL-14742,na,NULL,86 ± 4 IRHD
151598,A-BEFORE AGEING,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-DIA-2-MM-[10209][ESL]-GENERAL-14742,na,NULL,MIN. 56 KGF/CM²
151605,B-AFTER  ACCELERATED   AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-DIA-2-MM-[10209][ESL]-GENERAL-14742,na,NULL,89 ± 4 IRHD
151599,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-DIA-2-MM-[10209][ESL]-GENERAL-14742,na,NULL,MIN. 39.2 KGF/CM²
151596,B-WALL THICKNESS,ENDOTRACHEAL-TUBE-UNCUFFED-DISPOSABLE-DIA-2-MM-[10209][ESL]-GENERAL-14742,na,NULL,0.6 MM ±0.1 MM
151619,A-BEFORE     AGEING,ENDOTRACHEAL-UNCUFFED-TUBE-DIA-7-MM-(HARYANA)-GENERAL-14743,na,NULL,86 ± 4 IRHD
151613,A-BEFORE AGEING,ENDOTRACHEAL-UNCUFFED-TUBE-DIA-7-MM-(HARYANA)-GENERAL-14743,na,NULL,MIN. 56 KGF/CM²
151620,B-AFTER ACCELERATED AGEING AT 70°? 1?C  FOR  168  HOURS,ENDOTRACHEAL-UNCUFFED-TUBE-DIA-7-MM-(HARYANA)-GENERAL-14743,na,NULL,89 ± 4 IRHD
151614,B-AFTER ACCELERATED AGEING AT 70°? 1?C FOR 168 HOURS,ENDOTRACHEAL-UNCUFFED-TUBE-DIA-7-MM-(HARYANA)-GENERAL-14743,na,NULL,MIN. 39.2 KGF/CM²
151611,B-WALL THICKNESS,ENDOTRACHEAL-UNCUFFED-TUBE-DIA-7-MM-(HARYANA)-GENERAL-14743,na,NULL,1.0 MM ±0.1 MM
151714,<p>AVERAGE FILL</p>,EOPLATIN-INJECTION-(ZEE)-USP-14753,na,NULL,10 ML ± 5.0%
151715,<p>UNIFORMITY OF DOSAGE UNITS</p>,EOPLATIN-INJECTION-(ZEE)-USP-14753,na,NULL,± 9.0°OF AVG. FILL
151963,<p>SPECIFIC OPTICAL ROTATION</p>,ESCITALOPRAM-OXALATE-IP-14777,alphanumeric,+10.0°, +13.0?
152099,<p>SPECIFIC OPTICAL ROTATION (2%W/V SOLU.IN WATER)</p>,ESOMEPRAZOLE-SODIUM-STERILE-(OSPER)-GENERAL-14789,alphanumeric,+10.5°, +13.0?
152151,<p>IDENTIFICATION A</p>,ETAMSYLATE-BP-14795,alphanumeric,127°C , 134°C
152238,<p>SPECIFIC OPTICAL ROTATION</p>,ETHINYLOESTRADIOL-IP-14801,alphanumeric,-27°, -30°
152304,BOILING POINT,ETHYL-LACTATES-SOLUTION-GENERAL-14809,alphanumeric,NMT,154°C
152362,MELTING RANGE OR TEMPRATURE,ETHYL-VANILLIN-(IDEAL)-USP-14815,alphanumeric,76.0°, 78.0°
152401,<p>IDENTIFICATION B</p>,ETHYLPARABEN-USP-14819,alphanumeric,115°, 118°
152416,MELTING POINT,ETIZOLAM-GENERAL-14822,alphanumeric,196°C , 199°C
152571,LENGTH,ETOPOSIDE-(KABI)-GENERAL-14837,na,NULL,95% <200°?m
152572,WIDTH,ETOPOSIDE-(KABI)-GENERAL-14837,na,NULL,95% <20°?m
152676,FLASH POINT,EUCALYPTUS-OIL-(NILGIRI-KA-TEL)-IP-14847,alphanumeric,52.0°, 56.0°
152679,OPTICAL ROTATION,EUCALYPTUS-OIL-(NILGIRI-KA-TEL)-IP-14847,alphanumeric,+2.0°, +10.0°
153640,DIAMETER,FEBUXOSTAT-TABLET-(THEON)-GENERAL-14941,na,NULL,8.20 MM ±0.2 MM
153641,THICKNESS,FEBUXOSTAT-TABLET-(THEON)-GENERAL-14941,na,NULL,3.70 MM ±0.3 MM
153643,<p>UNIFORMITY OF WEIGHT</p>,FEBUXOSTAT-TABLET-(THEON)-GENERAL-14941,na,NULL,± 7.5% OF AVERAGE WEIGHT
153677,BREADTH,FEDROX-TABLET-(KWALITY)-USP-14946,na,NULL,9.05 MM ±2%
153678,HEIGHT,FEDROX-TABLET-(KWALITY)-USP-14946,na,NULL,6.20 MM ±2%
153676,LENGTH,FEDROX-TABLET-(KWALITY)-USP-14946,na,NULL,19.08 MM ±2%
153686,MICROBIAL TEST (TVC),FEDROX-TABLET-(KWALITY)-USP-14946,na,NULL,NMT 10³ CFU/GM
153722,<p>AVERAGE WEIGHT</p>,FENBENDAZOLE-BOLUS-(VET.)-(KWALITY)-GENERAL-14951,na,NULL,5.0 GM ± 5%
153725,MICROBIOLOGICAL TESTS,FENBENDAZOLE-BOLUS-(VET.)-(KWALITY)-GENERAL-14951,alphanumeric,NMT,NMT-10³ CFU/GM
153751,CONGEALING TEMPERATURE,FENNEL-OIL-USP-14955,alphanumeric,NLT,3.0°
153749,HEAVY METALS,FENNEL-OIL-USP-14955,alphanumeric,NMT,40 µg/g
153752,OPTICAL ROTATION,FENNEL-OIL-USP-14955,alphanumeric,+12.0°, +24.0°
43538,Active Ingredient (Fenpropathrin Content) (% by mass),FENPROPATHRIN-30%-EC-(IS:-15162-2002)-NABL-4652,na,NULL,30°±5% of the nominal value
43541,<p>Flash Point (Abel)</p>,FENPROPATHRIN-30%-EC-(IS:-15162-2002)-NABL-4652,na,NULL,Above 24.5°C
153862,LIMIT OF ARSENIC,FERIC-OXIDE-RED-(ARISTO)-USP-14966,alphanumeric,NMT,3.0 µg/g
153863,LIMIT OF MERCURY,FERIC-OXIDE-RED-(ARISTO)-USP-14966,alphanumeric,NMT,3.0 µg/g
153869,LIMIT OF ARSENIC,FERIC-OXIDE-RED-30E172-(COL.-IRON-OXIDE-YELLOW)-USP-14967,alphanumeric,NMT,3.0 µg/g
153870,LIMIT OF MERCURY,FERIC-OXIDE-RED-30E172-(COL.-IRON-OXIDE-YELLOW)-USP-14967,alphanumeric,NMT,3.0 µg/g
153912,LIMIT OF ARSENIC,FERRIC-OXIDE-(SICOVIT-YELLOW-10E172)-USP-14973,alphanumeric,NMT,3.0 µg/g
153910,MERCURY,FERRIC-OXIDE-(SICOVIT-YELLOW-10E172)-USP-14973,alphanumeric,NMT,3.0 µg/g
154082,<p>AVERAGE WEIGHT</p>,FERROUS-SULPHATE-TABLET-[KWALITY]-IP-14989,na,NULL,420 MG (LIMIT ± 5%)
154080,DIAMETER,FERROUS-SULPHATE-TABLET-[KWALITY]-IP-14989,na,NULL,9.30 MM ±5%
154086,HARDNESS,FERROUS-SULPHATE-TABLET-[KWALITY]-IP-14989,na,NULL,NLT 4.0 KG/CM²
154087,MICROBIAL TEST (TVC),FERROUS-SULPHATE-TABLET-[KWALITY]-IP-14989,na,NULL,NMT 10³ CFU/GM
154081,THICKNESS,FERROUS-SULPHATE-TABLET-[KWALITY]-IP-14989,na,NULL,4.90 MM ±5%
154109,DIAMETER,FEXOFENADINE-HCL.-TABLET-(THEON)-IP-14992,na,NULL,9.60 MM ±0.2 MM
154110,THICKNESS,FEXOFENADINE-HCL.-TABLET-(THEON)-IP-14992,na,NULL,4.30 MM ±0.3 MM
154343,HARDNESS,"FLORICOT-TABLET-(SAMARTH,-BADDI)-IP-15013",na,NULL,NLT 3.0 KG/CM²
154339,<p>UNIFORMITY OF WEIGHT VARIATION</p>,"FLORICOT-TABLET-(SAMARTH,-BADDI)-IP-15013",na,NULL,±7.5% OF AVG. WT.
154612,OPTICAL ROTATION,FLUOXETINE-HYDROCHLORIDE-IP-15039,alphanumeric,-0.05°, + 0.05°
154766,<p>SPECIFIC OPTICAL ROTATION</p>,FLUTICASONE-PROPIONATE-BP-15056,alphanumeric,+32.0°, +36.0°
154802,MELTING RANGE OR TEMPRATURE,FLUVOXAMINE-MALEATE-USP-15060,alphanumeric,121° , 123°
154861,<p>SPECIFIC OPTICAL ROTATION</p>,FOLIC-ACID-BP-15066,alphanumeric,+19.8°, +22.0°
154844,<p>SPECIFIC OPTICAL ROTATION</p>,FOLIC-ACID-IP-15065,alphanumeric,+18°, +22°
63141,Total Dye content (% by mass) (on dry basis),FOOD-COLOUR-NABL-5882,na,NULL,±7.5% of the nominal value
154999,OPTICAL ROTATION,FORMOTEROL-FUMARATE-DIHYDRATE-IP-15081,alphanumeric,-0.10°, +0.10°
155008,AVERAGE WEIGHT OF 10 CONTAINERS,FORTIFIED-PROCAINE-PENICILLIN-INJECTION-(KWALITY)-IP-15082,na,NULL,3.60GM ± 10%
155241,HARDNESS IN KG/CM²,FRUSEMIDE-TABLET-(LA-CHEMICO)-IP-15102,alphanumeric,NLT,3.0 KG/CM²
155243,<p>UNIFORMITY OF WEIGHT</p>,FRUSEMIDE-TABLET-(LA-CHEMICO)-IP-15102,na,NULL,[± 7.5% OF AV. WT.]
155345,<p>AVERAGE WEIGHT</p>,FUROMAX-C-625-TABLET-(THEON)-GENERAL-15114,na,NULL,1090 MG ± 5%
155341,LENGTH,FUROMAX-C-625-TABLET-(THEON)-GENERAL-15114,na,NULL,21.20 MM ±0.2 MM
155343,THICKNESS,FUROMAX-C-625-TABLET-(THEON)-GENERAL-15114,na,NULL,6.40 MM ±0.3 MM
155342,WIDTH,FUROMAX-C-625-TABLET-(THEON)-GENERAL-15114,na,NULL,10.20 MM ±0.2 MM
155601,LENGTH,GABAPENTIN-&-MECOBALAMIN-TABLET-(THEON)-GENERAL-15141,na,NULL,17.10 MM ±0.2 MM
155603,THICKNESS,GABAPENTIN-&-MECOBALAMIN-TABLET-(THEON)-GENERAL-15141,na,NULL,5.20 MM ±0.3 MM
155602,WIDTH,GABAPENTIN-&-MECOBALAMIN-TABLET-(THEON)-GENERAL-15141,na,NULL,7.10 MM ±0.2 MM
155709,MASS GM/M?,GAUGE-CLOTH-(MEDICAL)-20M-X-100CM²[1045][ESL]-GENERAL-15151,na,NULL,30 ± 5
155852,<p>SPECIFIC OPTICAL ROTATION</p>,GEMCITABINE-HYDROCHLORIDE-IP-15161,alphanumeric,+43.0°, +50.0°
155997,GENTAMICIN SULPHATE,GENTAMICIN-SULPHATE-IP-15173,alphanumeric,NLT,590 µg/mg (ON DRIED BASIS)
155989,<p>SPECIFIC OPTICAL ROTATION</p>,GENTAMICIN-SULPHATE-IP-15173,alphanumeric,+107°, +121°
58390,Ethyl alcohol content(% by volume 20?/20°under 65? to 87.5? Proof),GIN-(IS:4100-2005)-NABL-5544,na,NULL,37 ± 3 % by volume of the declared strength
156233,<p>IDENTIFICATION A</p>,GLIBENCLAMIDE-BP-15199,alphanumeric,169°, 179°
156494,3-THICKNESS ?,GLOVES-SURGICAL-DISPOSABLE-6--INCH-[5570][ESL]-GENERAL-15222,na,NULL,0.24 MM ±0.0°MM
156510,3-THICKNESS ?,GLOVES-SURGICAL-DISPOSABLE-7---1/2-INCH-[893][ESL]-GENERAL-15223,na,NULL,0.24 MM ±0.0°MM
156526,3-THICKNESS ?,GLOVES-SURGICAL-DISPOSABLE-8-INCH-[10369][ESL]-GENERAL-15224,na,NULL,0.24 MM ±0.0°MM
156542,THICKNESS,GLOVES-SURGICAL-EXAMINATION-LATEX-LARGE-SIZE-[5303][ESL]-GENERAL-15225,na,NULL,0.24 MM ±0.0°MM
156558,THICKNESS,"GLOVES,-SURGICAL-EXAMINATION-LATEX-MEDIUIM-[5302][ESL]-GENERAL-15226",na,NULL,0.24 MM ±0.0°MM
156574,3-THICKNESS ?,"GLOVES,-SURGICAL,-DISPOSABLE-6.5-INCH-[891][ESL]-GENERAL-15227",na,NULL,0.24 MM ±0.0°MM
156590,3-THICKNESS ?,"GLOVES,-SURGICAL,-DISPOSABLE-7-INCH-[892][ESL]-GENERAL-15228",na,NULL,0.24 MM ±0.0°MM
156611,OPTICAL ROTATION,GLUCOSAMINE-HYDROCHLORIDE-USP-15229,alphanumeric,+70.0°, +73.0°
156634,<p>SPECIFIC OPTICAL ROTATION</p>,GLUCOSAMINE-SULPHATE-POTASSIUM-CHLORIDE-(COSMAS)-USP-15231,alphanumeric,47, +53.0°
156622,<p>SPECIFIC OPTICAL ROTATION</p>,GLUCOSAMINE-SULPHATE-POTASSIUM-CHLORIDE-USP-15230,alphanumeric,47, +53.0°
156654,<p>SPECIFIC OPTICAL ROTATION</p>,GLUCOSAMINE-SULPHATE-SODIUM-CHLORIDE-USP-15233,alphanumeric,47, +53.0°
156698,<p>SPECIFIC OPTICAL ROTATION</p>,GLUCOSE-D-[2221][U]-IP-15237,alphanumeric,52.5, +53.3°
156935,<p>IDENTIFICATION A</p>,GLYCEROL-DIBEHENATE-(COMPRITOL-888-ATO)STERLLIERSTER-DBHG-BP-15257,alphanumeric,65°C , 77°C
61779,<p>Flash Point (Abel)</p>,GLYPHOSATE-41%-SL-FSSAI-5755,na,NULL,Above 24.5°C
157220,HARDNESS,GRIPCIL-TABLET-(BIODEAL)-GENERAL-15287,alphanumeric,NMT,3.0 KG/CM²
157339,<p>IDENTIFICATION C</p>,GUAIPHENESIN-(ILT)-IP-15298,alphanumeric,79°C , 83°C
157317,<p>IDENTIFICATION C</p>,GUAIPHENESIN-IP-15297,alphanumeric,79°C , 83°C
157418,MELTING POINT,GWHITE-VCE-GENERAL-15305,alphanumeric,112°C , 115°C
157611,HARDNESS IN KG/CM²,HALOPERIDOL-TABLET-[LA-CHEMICO]-IP-15326,alphanumeric,NLT,2.0 KG/CM²
157612,<p>UNIFORMITY OF WEIGHT</p>,HALOPERIDOL-TABLET-[LA-CHEMICO]-IP-15326,na,NULL,[± 7.5% OF AV. WT.]
157621,DISTILLATION RANGE,HALOTHANE-FOR-INHALATION-[315][S]-BP-15327,alphanumeric,BETWEEN 49.0°, 51.0°C
157640,MASS GM/M?,HANDLOOM-COTTON-BANDAGE-CLOTH-BLEACHED-NON-STERILISED-(ODISHA-GOVT.)-GENERAL-15330,na,NULL,(57±5 GM/M²)
157659,MASS GM/M?,"HANDLOOM-COTTON-GAUZE,-BLEACHED-ABSORBENT-(IS:758/88-SPF.)-(ODISHA-GOVT.)-GENERAL-15331",na,NULL,30±5 GM/M²
157674,MASS GM/M?,"HANDLOOM-COTTON-GAUZE,-BLEACHED-ABSORBENT,-NON-STERILISED-(ODISHA-GOVT.)-GENERAL-15332",na,NULL,30±5 GM/M²
157704,CONGEALING RANGE,HARD-PARAFFINE-IP-15337,alphanumeric,50°, 60°
61880,<p>Flash Point (Abel)</p>,HEXACONAZOLE-5%-EC-FSSAI-5768,na,NULL,24.5°C
63999,Flash Point (Abel) [Cl.3.2.3],HEXACONAZOLI-5%-EC-(BIS)-NABL-5954,na,NULL,24.5°C
158173,SELENIUM,HYDROCHLOROTHIAZIDE-(RESIDUE)-GENERAL-15388,alphanumeric,NLT,60°
158212,<p>SPECIFIC OPTICAL ROTATION</p>,HYDROCORTISONE-ACETATE-IP-15391,alphanumeric,+158°, +167°
158363,<p>IDENTIFICATION A</p>,HYDROGENATED-CASTOR-OIL-BP-15404,alphanumeric,83°C , 88°C
158401,MELTING RANGE,HYDROGENETED-CASTROL-OIL-IP-15407,alphanumeric,85.0°, 88.0°
158416,MELTING RANGE,HYDROQUINONE-USP-15408,alphanumeric,172° , 174°
158487,LEAD,HYDROXY-ETHYL-CELLULOSE-(NATROSAL-250-HR)-GENERAL-15417,alphanumeric,NMT,10 µg/g
158493,HEAVY METALS,HYDROXY-ETHYL-CELLULOSE-(SENTISS)-GENERAL-15418,alphanumeric,NMT, 20 µg/g
158620,<p>SPECIFIC OPTICAL ROTATION</p>,HYDROXYPROGESTERONE-CAPROATE-IP-15429,alphanumeric,+44°, +49°
158628,MELTING RANGE,HYDROXYPROGESTERONE-CAPROATE-USP-15430,alphanumeric,120°, 124°
158629,SPECIFIC ROTATION,HYDROXYPROGESTERONE-CAPROATE-USP-15430,alphanumeric,+58°, +64°
158668,<p>SPECIFIC OPTICAL ROTATION</p>,HYDROXYPROGESTERONE-HEXANOATE-IP-15434,alphanumeric,+44.0°, +49.0°
158780,HARDNESS,HYDROXYZINE-TABLET-(KWALITY)-IP-15446,alphanumeric,NLT,4.5 KG/CM²
158787,MICROBIAL LIMIT (TVC),HYDROXYZINE-TABLET-(KWALITY)-IP-15446,alphanumeric,NMT,10°CFU/GM
158795,<p>SPECIFIC OPTICAL ROTATION</p>,HYOSCINE-BUTYLBROMIDE-IP-15447,alphanumeric,-18°, -20°
158915,IDENTIFICATION E (FLOCCULATION TEMPERATURE),HYPROMELLOSE-(HPMC)-CPS-15-(PHARMACOAT-615)-USP-15458,alphanumeric,NLT,50.0°
159315,OPTICAL ROTATION,IBUPROFEN-(MACLEODS)-BP-15501,alphanumeric,-0.05°, +0.05°
159278,OPTICAL ROTATION,IBUPROFEN-IP-15499,alphanumeric,+0.05°, -0.05°
159381,HARDNESS IN KG/CM²,IBUPROFEN-TABLET-(LA-CHEMICO)-IP-15507,na,NULL,NLT 4.0 KG/CM²
159382,<p>UNIFORMITY OF WEIGHT</p>,IBUPROFEN-TABLET-(LA-CHEMICO)-IP-15507,na,NULL,[±5% OF AV. WT.]
58183,<p>Agaric Acid (ppm)</p>,ICE-TEA-PREMIX-NABL-5531,na,NULL,MAX. 10µg/Kg
58184,<p>Hydrocyanic Acid (ppm)</p>,ICE-TEA-PREMIX-NABL-5531,na,NULL,MAX. 5.0 µg/Kg
58153,<p>Hypericine (ppm)</p>,ICE-TEA-PREMIX-NABL-5531,na,NULL,MAX. 1.0 µg/Kg
58154,<p>Saffrole (ppm)</p>,ICE-TEA-PREMIX-NABL-5531,na,NULL,MAX. 10.0 µg/Kg
62608,<p>Flash Point (Abel)</p>,IMIDACLOPRID-17.8-%-SL(IS:15335-2003)-FSSAI-5838,na,NULL,Above 24.5°C
62609,Imidacloprid content (% by mass),IMIDACLOPRID-17.8-%-SL(IS:15335-2003)-FSSAI-5838,na,NULL,17.8% ±5% of the nominal value
57225,Imidacloprid content (% by mass) [Cl:3.3.1],IMIDACLOPRID-30.5%-SC-(IS:16131-2015)-FSSAI-5449,na,NULL,30.5 ±5% of the nominal value
159675,HEAVY METALS,INDIAN-294-(POLACRILLIN-POTASSIUM)-USP-15535,alphanumeric,NMT, 20 µg/g
159719,<p>UNIFORMITY OF WEIGHT</p>,INDU-CU-CO-GENERAL-15540,na,NULL,(± 5%)
159774,CONDUCTIVITY,INOSITOL-USP-15547,alphanumeric,NMT,20 µS /CM
159770,<p>IDENTIFICATION B</p>,INOSITOL-USP-15547,alphanumeric,224°, 227°
164680,OPTICAL ROTATION,L-LYSINE-HYDROCHLORIDE-USP-16007,alphanumeric,+20.4°, +21.4°
164720,OPTICAL ROTATION,L-METHIONINE-(NAXPAR)-USP-16011,alphanumeric,+22.4°, 24.7°
164707,OPTICAL ROTATION,L-METHIONINE-USP-16010,alphanumeric,+22.4°, 24.7°
165126,HEAVY METALS,L-TRYPTOPHAN-(NAXPAR)-USP-16052,alphanumeric,NMT,10 µg/g
165132,OPTICAL ROTATION,L-TRYPTOPHAN-(NAXPAR)-USP-16052,alphanumeric,-30.0°, -38.0°
165110,HEAVY METALS,L-TRYPTOPHAN-USP-16051,alphanumeric,NMT,10 µg/g
165116,OPTICAL ROTATION,L-TRYPTOPHAN-USP-16051,alphanumeric,-30.0°, -38.0°
165149,<p>SPECIFIC OPTICAL ROTATION</p>,L-TYROSINE-USP-16053,alphanumeric,-9.8°, -11.2°
165247,OPTICAL ROTATION,L-VALINE-(NAXPAR)-USP-16063,alphanumeric,+26.6°, +28.8°
165271,OPTICAL ROTATION,L-VALUE-USP-16064,alphanumeric,+26.6°, +28.8°
162032,<p>SPECIFIC OPTICAL ROTATION</p>,L+TARTRIC-ACID-GENERAL-15752,alphanumeric,+12.0°, +13.0°
162648,DIAMETER,LABETALOL-TABLET-(KWALITY)-IP-15819,na,NULL,8.0°MM ±2%
162657,HARDNESS,LABETALOL-TABLET-(KWALITY)-IP-15819,alphanumeric,NLT,8.0 KG/CM²
162661,MICROBIAL TEST (TVC),LABETALOL-TABLET-(KWALITY)-IP-15819,na,NULL,NMT 10°CFU/GM
162649,THICKNESS,LABETALOL-TABLET-(KWALITY)-IP-15819,na,NULL,3.80 MM ±2%
162796,<p>SPECIFIC OPTICAL ROTATION</p>,LACTOSE-MONOHYDRATE-(MACLEODS)-USP-15830,alphanumeric,+54.5°, +55.9°
162770,<p>SPECIFIC OPTICAL ROTATION</p>,LACTOSE-MONOHYDRATE-IP-15828,alphanumeric,+54.4°, +55.9°
162783,HEAVY METALS,LACTOSE-MONOHYDRATE-USP-15829,alphanumeric,NMT,5.0 µg/g
162785,OPTICAL ROTATION,LACTOSE-MONOHYDRATE-USP-15829,alphanumeric,+54.4°, +55.9°
63683,Lambda Cyhalothrin content (% by mass),LAMBDA-CYHALOTHRIN-10%-WP-FSSAI-5917,na,NULL,±10°of the nominal value (10°gm/Kg)
39613,Lambda Cyhalothrin content (% by mass) [Cl:3.3 (i)],LAMBDA-CYHALOTHRIN-WP-(IS:14510-1997)-NABL-4412,na,NULL,10 ±5% of the nominal value
162905,<p>SPECIFIC OPTICAL ROTATION</p>,LAMIVUDINE-USP-15844,alphanumeric,-98.0°, -92.5?
163021,DIAMETER,LANSOPRAZOLE-TABLETS-GENERAL-15852,na,NULL,13.10mm±3%
163022,HARDNESS,LANSOPRAZOLE-TABLETS-GENERAL-15852,alphanumeric,NLT,2.0 KG/CM²
163019,THICKNESS,LANSOPRAZOLE-TABLETS-GENERAL-15852,na,NULL,4.80 mm±3%
163245,OPTICAL ROTATION,LEMON-OIL-(LOVINCARE)-BP-15873,alphanumeric,+57°, +70?
163223,OPTICAL ROTATION,LEMON-OIL-BP-15872,alphanumeric,++57.0°, +70.0?
163367,MICROBIOLOGICAL TESTS,LEVAMISOLE-&-OXYCLOZANIDE-BOLUS-(VET.)-(KWALITY)-GENERAL-15886,alphanumeric,NMT,10°CFU/GM
163386,<p>IDENTIFICATION C</p>,LEVAMISOLE-HYDROCHLORIDE-IP-15889,alphanumeric,-121° , -128°
163387,IDENTIFICATION D,LEVAMISOLE-HYDROCHLORIDE-IP-15889,alphanumeric,58? , 61°
163392,<p>SPECIFIC OPTICAL ROTATION</p>,LEVAMISOLE-HYDROCHLORIDE-IP-15889,alphanumeric,-121° , -128°
163521,OPTICAL ROTATION,LEVOCARNITINE-USP-15901,alphanumeric,-29.0°, -32.0°
163534,<p>SPECIFIC OPTICAL ROTATION</p>,LEVOCETIRIZINE-DIHYDROCHLORIDE-IP-15903,alphanumeric,+10°, +14°
163648,OPTICAL ROTATION,LEVOFLOXACIN-HEMIHYDRATE-(MACLEODS)-USP-15913,alphanumeric,-92? , -106°
163625,OPTICAL ROTATION,LEVOFLOXACIN-HEMIHYDRATE-USP-15911,alphanumeric,-92? , -106°
163689,BREADTH,LEVOFLOXACIN-TABLET-(KWALITY)-USP-15916,na,NULL,8.12 MM ±3%
163699,HARDNESS,LEVOFLOXACIN-TABLET-(KWALITY)-USP-15916,na,NULL,NLT 2.0 KG/CM²
163690,HEIGHT,LEVOFLOXACIN-TABLET-(KWALITY)-USP-15916,na,NULL,5.67 MM ±3%
163688,LENGTH,LEVOFLOXACIN-TABLET-(KWALITY)-USP-15916,na,NULL,16.43 MM ±3%
163715,<p>IDENTIFICATION C</p>,LEVONORGESTREL-IP-15918,alphanumeric,NMT,237°
163716,<p>SPECIFIC OPTICAL ROTATION</p>,LEVONORGESTREL-IP-15918,alphanumeric,-30.0°, -35.0°
163757,<p>SPECIFIC OPTICAL ROTATION</p>,LEVOSALBUTAMOL-SULPHATE-(RAVENBHEL-HEALTHCARE)-IP-15922,alphanumeric,-30°, -40°
163741,<p>SPECIFIC OPTICAL ROTATION</p>,LEVOSALBUTAMOL-SULPHATE-IP-15921,alphanumeric,-30°,-40?
163787,HARDNESS,LEVOSULPIRIDE-SUSTAINED-RELEASE-TABLETS-(BIODEAL)-GENERAL-15925,alphanumeric,NLT,2.0 KG/CM²
163802,OPTICAL ROTATION,LEVOTHYROXINE-SODIUM-USP-15926,alphanumeric,-5.0°, -6.0?
163920,ARSENIC,LICORICE-EXTRACT-40%-(CA)-GENERAL-15935,alphanumeric,NLT,1.0 PPM (µg/mg)
163921,CADMIUM,LICORICE-EXTRACT-40%-(CA)-GENERAL-15935,alphanumeric,NLT,1.0 PPM (µg/mg)
163919,LEAD,LICORICE-EXTRACT-40%-(CA)-GENERAL-15935,alphanumeric,NLT,3.0 PPM (µg/mg)
163922,MERCURY,LICORICE-EXTRACT-40%-(CA)-GENERAL-15935,alphanumeric,NLT,0.1 PPM (µg/mg)
163918,TOTAL HEAVY METALS (PB),LICORICE-EXTRACT-40%-(CA)-GENERAL-15935,alphanumeric,NLT,20 PPM (µg/mg)
163950,MELTING RANGE,LIDOCAINE-USP-15937,alphanumeric,74°C , 79°C
164172,AVERAGE WEIGHT OF 5 CONTAINERS,LIGNOCAINE-HYDROCHLORIDE-GEL-(KWALITY)-IP-15960,na,NULL,30.0 GM ± 9%
164241,<p>SPECIFIC OPTICAL ROTATION</p>,LINCOMYCIN-HYDROCHLOEIDE-IP-15966,alphanumeric,+135°, +150°
164309,<p>SPECIFIC OPTICAL ROTATION</p>,LINEZOLID-IP-15973,alphanumeric,-9.0°, -140°
164425,HEAVY METALS,LIQUID-GLUCOSE-USP-15983,alphanumeric,NMT,10 µg/mg
164568,HARDNESS IN KG/CM²,LITHIUM-CARBONATE-TABLET-[LA-CHEMICO]-IP-15998,alphanumeric,NLT,5.0 KG/CM²
164570,<p>UNIFORMITY OF WEIGHT</p>,LITHIUM-CARBONATE-TABLET-[LA-CHEMICO]-IP-15998,na,NULL,[± 5% OF AV. WT.]
61604,"Enterobacteriacae, cfu/ml",LOHSAV-NABL-5736,na,NULL,Max. 10
61605,"Total Fungal count,cfu/ml",LOHSAV-NABL-5736,na,NULL,Max. 10?
164916,HARDNESS,LORAZEPAM-TABLET-(KWALITY)-BP-16030,alphanumeric,NLT,4.5 KG/CM²
164917,MICROBIAL LIMITS (TVC),LORAZEPAM-TABLET-(KWALITY)-BP-16030,alphanumeric,NMT,10°CFU/GM
164926,HARDNESS IN KG/CM²,LORAZEPAM-TABLET-(LA-CHEMICO)-IP-16031,alphanumeric,NLT,3.0 KG/CM²
165004,DIAMETER,LOSARTAN-POTASSIUM-&-HYDROCHLOROTHIAZIDE-TABLET-(THEON)-GENERAL-16039,na,NULL,8.10 MM ±0.2 MM
165005,THICKNESS,LOSARTAN-POTASSIUM-&-HYDROCHLOROTHIAZIDE-TABLET-(THEON)-GENERAL-16039,na,NULL,3.80 MM ±0.3 MM
39882,pH (5% aqueous solution) ,LOW-SODIUM-SALT-NABL-4425,na,NULL,7 ±0.5
39874,Potassium Chloride (mg),LOW-SODIUM-SALT-NABL-4425,na,NULL,14.5 ±0.5
39875,<p>Sodium chloride (% by mass)</p>,LOW-SODIUM-SALT-NABL-4425,na,NULL,84.5 ±0.5
165189,MELTING RANGE,LUMEFANTRINE-GENERAL-16056,alphanumeric,125°, 131°
166578,ARSENIC,MAGNESIUM-ALUMINIUM-META-SILICATE-USP-16181,alphanumeric,NMT,3.0 µg/g
166584,HEAVY METALS,MAGNESIUM-ALUMINIUM-META-SILICATE-USP-16181,alphanumeric,NMT,30 µg/g
166636,HEAVY METALS,MAGNESIUM-HYDROXIDE-USP-16186,alphanumeric,NMT,20 µ/g
166757,<p>IDENTIFICATION A</p>,MAGNESIUM-STEARATE-(HETERO)-IP-16191,alphanumeric,NLT,53°
166736,<p>SPECIFIC OPTICAL ROTATION</p>,MAGNESIUM-STEARATE-(HETERO)-USP-16190,alphanumeric,-0.05°, -0.15°
166777,<p>SPECIFIC OPTICAL ROTATION</p>,MAGNESIUM-STEARATE-(KABI)-USP-16192,alphanumeric,-0.05°, -0.15°
166794,<p>IDENTIFICATION A</p>,MAGNESIUM-STEARATE-(USP/IP/BP)-BP-16194,na,NULL,MIN. 53°C
166702,<p>IDENTIFICATION A</p>,MAGNESIUM-STEARATE-BP-16189,alphanumeric,NMT,53°C
166664,FREEZING POINT,MAGNESIUM-STEARATE-IP-16187,alphanumeric,NLT,53.0°
166958,<p>SPECIFIC OPTICAL ROTATION</p>,MALIC-ACID-(HETERO)-IP-16208,alphanumeric,-0.10°, +0.10°
166943,<p>SPECIFIC OPTICAL ROTATION</p>,MALIC-ACID-IP-16207,alphanumeric,-0.10°, +0.10°
167195,<p>SPECIFIC OPTICAL ROTATION</p>,MANNITOL-(HETERO)-IP-16226,alphanumeric,+23.0°, +25.0?
167221,CONGEALING RANGE,MANNITOL-(PEARLITOL-SD200)-IP-16228,alphanumeric,27°, 28°
167220,<p>SPECIFIC OPTICAL ROTATION</p>,MANNITOL-(PEARLITOL-SD200)-IP-16228,alphanumeric,+23°, +25°
167242,<p>IDENTIFICATION A</p>,MANNITOL-INJECTION-(ODISHA-GOVT.)-IP-16230,alphanumeric,165°, 170°
167254,IDENTIFICATION A BY MELTING POINT OF THE RESIDUE,MANNITOL-INTRAVENOUS-INFUSION-(JAMMU-GOVT.)-BP-16231,na,NULL,ABOUT 167°
167139,IDENTIFICATION (D MELTING POINT),MANNITOL-IP-16223,alphanumeric,165°, 170°
167142,<p>SPECIFIC OPTICAL ROTATION</p>,MANNITOL-IP-16223,alphanumeric,+23.0°, +25.0°
167271,CONDDUCTIVITY,MANNITOL-PH.-EUR.-GENERAL-16232,alphanumeric,NMT,20 µS
167180,CONDUCTIVITY,MANNITOL-USP-16225,alphanumeric,NMT,20 µs/CM
167179,MELTING RANGE OR TEMPRATURE,MANNITOL-USP-16225,alphanumeric,165°, 170°
167173,<p>NICKEL</p>,MANNITOL-USP-16225,alphanumeric,NMT,1.0 µg/gM
167658,<p>SPECIFIC OPTICAL ROTATION</p>,MEDROXYPROGESTERONE-ACETATE-BP-16260,alphanumeric,+47.0°, +53.0°
167673,<p>SPECIFIC OPTICAL ROTATION</p>,MEDROXYPROGESTERONE-ACETATE-IP-16261,alphanumeric,+45? , +51°
167766,HARDNESS,MEFENAMIC-ACID-TABLET-BP-(500-MG)-(KWALITY)-BP-16270,alphanumeric,NLT,8.0 KG/CM²
167841,<p>SPECIFIC OPTICAL ROTATION</p>,MEGLUMINE-BP-16277,alphanumeric,-16°, -17°
167822,<p>SPECIFIC OPTICAL ROTATION</p>,MEGLUMINE-USP-16275,alphanumeric,-15.5°, -17.5°
168016,CONGEALING TERMPERATURE,MENTHOL-(IDEAL/IP/USP/BP)-USP-16292,alphanumeric,27°, 28°
168015,MELTING RANGE,MENTHOL-(IDEAL/IP/USP/BP)-USP-16292,alphanumeric,41.0°, 44.0°
168017,SPECIFIC ROTATION,MENTHOL-(IDEAL/IP/USP/BP)-USP-16292,alphanumeric,-45° , -51°
167993,CONGEALING RANGE,MENTHOL-IP-16290,alphanumeric,27°, 28°
167992,<p>SPECIFIC OPTICAL ROTATION</p>,MENTHOL-IP-16290,alphanumeric,-49.0°, -51.0°
168008,1-L-MENTHOL,MENTHOL-USP-16291,alphanumeric,-45° , -51°
168009,2-DL-MENTHOL,MENTHOL-USP-16291,alphanumeric,-2? , +2°
168000,"<p>IDENTIFICATION BY B, OPTICAL ROTATION</p>",MENTHOL-USP-16291,alphanumeric,-45° , -51°
168010,MELTING RANGE,MENTHOL-USP-16291,alphanumeric,41°, 44°
168445,HARDNESS IN KG/CM²,METFORMIN-TABLET-(LA-CHEMICO)-IP-16327,alphanumeric,NLT,4.0 KG/CM²
168447,<p>UNIFORMITY OF WEIGHT</p>,METFORMIN-TABLET-(LA-CHEMICO)-IP-16327,na,NULL,[± 5% OF AV. WT.]
168504,HEAVY METALS,METHACRYLIC-ACID-COPOLYMER-TYPE-C-USP-16334,alphanumeric,NMT,20 µg/g
168523,HEAVY METALS,METHACRYLIC-ACID-TYPE-C-(L-100-55)-USP-16336,alphanumeric,NMT,20 µg/g
168587,OPTICAL ROTATION,METHIONINE-USP-16342,alphanumeric,+22.4°, +24.7°
168697,MELTING POINT,METHYL-PARABEN-GENERAL-16353,alphanumeric,125°C , 128°C
168834,MELTING RANGE OR TEMPRATURE,METHYL-SULPHONYL-METHANE(CLEVUS)-USP-16363,alphanumeric,108.5°, 110.5°
168919,OPTICAL ROTATION,METHYLDOPA-IP-16371,alphanumeric,-1.10°, -1.23°
168950,OPTICAL ROTATION,"METHYLDOPA-TABLET-(JACKSON,-AMRITSAR)-IP-16374",alphanumeric,-0.98°, -1.09°
168941,OPTICAL ROTATION,METHYLDOPA-TABLET-IP-16373,alphanumeric,-0.98°, -1.09°
169285,<p>SPECIFIC OPTICAL ROTATION</p>,METOPROLOL-TARTRATE-IP-16407,alphanumeric,+7.0°, +10.0°
169407,<p>IDENTIFICATION A</p>,METRONIDAZOLE-BENZOATE-BP-16418,alphanumeric,99°C , 102°C
169378,<p>IDENTIFICATION A</p>,METRONIDAZOLE-BP-16416,alphanumeric,159°C , 163°C
169584,HARDNESS IN KG/CM²,METRONIDAZOLE-TABLET-(LA-CHEMICO)-IP-16433,na,NULL,NLT 4 KG/CM²
57013,Metsulfuron Methyl content (% by mass),METSULFURON-METHYL-20%-WP-FSSAI-5430,na,NULL,20± 5% of the nominal value
169620,AVERAGE WEIGHT OF 10 CONTAINERS,MICONAZOLE-CREAM-(KWALITY)-BP-16437,na,NULL,15.0 GM ± 9%
169896,.NET CONTENT PER BOTTLE,MICROSHIELD--4-GENERAL-16457,na,NULL,500ML PACK (505± 5ML/512.2?5 G)
169895,NET CONTENT PER BOTTLE,MICROSHIELD--4-GENERAL-16457,na,NULL,100ML PACK (105± 5ML/106.5?5 G)
169993,.FILL VOLUME,MICROSHIELD--T-HAND-CLEANSER-GENERAL-16463,na,NULL,5050 ± 50 ML
169992,FILL VALUME,MICROSHIELD--T-HAND-CLEANSER-GENERAL-16463,na,NULL,50 ± 5 ML
169991,TRICLOSAN CONTENT %W/W,MICROSHIELD--T-HAND-CLEANSER-GENERAL-16463,na,NULL,0.50 ±0.05%
169914,NET CONTENT PER BOTTLE,MICROSHIELD-HANDRUB-GENERAL-16459,na,NULL,50 ± 5 ML
169947,..NET CONTENT PER BOTTLE,MICROSHIELD-PVP-S-(POVIDONE-IODINE-ANTISEPTIC-SOLUTION)-GENERAL-16461,na,NULL,50 ± 25ML/5294 ± 26 G
169946,.NET CONTENT PER BOTTLE,MICROSHIELD-PVP-S-(POVIDONE-IODINE-ANTISEPTIC-SOLUTION)-GENERAL-16461,na,NULL,50±  5ML/533 ± 5 G
169945,NET CONTENT PER BOTTLE,MICROSHIELD-PVP-S-(POVIDONE-IODINE-ANTISEPTIC-SOLUTION)-GENERAL-16461,na,NULL,10±  5ML/111 ± 5 G
169968,.NET CONTENT PER BOTTLE,MICROSHIELD-PVP-S-(POVIDONE-IODINE-SURGICAL-HANDWASH)-GENERAL-16462,na,NULL,50±  5ML/533 ± 5 G
169967,NET CONTENT PER BOTTLE,MICROSHIELD-PVP-S-(POVIDONE-IODINE-SURGICAL-HANDWASH)-GENERAL-16462,na,NULL,10±  5ML/111 ± 5 G
170012,NET CONTENT PER BOTTLE,MICROSHIELD-TINCTURE-GENERAL-16464,na,NULL,50± 5 ML
170071,OPTICAL ROTATION,MIFEPRISTONE-IP-16470,alphanumeric,124° , 129°
170281,OPTICAL ROTATION,MIRTAZAPINE-IP-16489,alphanumeric,-0.10°, +0.10°
170377,LENGTH,MISOPROSTOL-TABLET-(200-MCG)-(THEON)-IP-16497,na,NULL,11.90 MM ±0.2 MM
170379,THICKNESS,MISOPROSTOL-TABLET-(200-MCG)-(THEON)-IP-16497,na,NULL,4.50 MM ±0.3 MM
170378,WIDTH,MISOPROSTOL-TABLET-(200-MCG)-(THEON)-IP-16497,na,NULL,6.90 MM ±0.2 MM
170455,LIMIT OF SULFUR DIOXIDE,MODIFIED-STARCH-GENERAL-16504,na,NULL,NMT 50 µg/g
170551,MICROBIAL LIMITS (TVC),MOLTEM-SUSPENSION-(PARACETAMOL-ORAL-SUSPENSION)-(KWALITY)-BP-16511,alphanumeric,NMT,10°CFU/GM
170576,<p>SPECIFIC OPTICAL ROTATION</p>,MOMETASONE-FUROATE-IP-16514,alphanumeric,+50°, +55°
170590,HEAVY METALS,MOMETASONE-FUROATE-USP-16515,alphanumeric,NMT,30 µg/g
170592,OPTICAL ROTATION,MOMETASONE-FUROATE-USP-16515,alphanumeric,+56°, +62°
63392,<p>Flash Point (Abel)</p>,MONOCROTOPHOS-36-%-SL(IS:8074-1990)-FSSAI-5902,na,NULL,Above 24.5°C
63393,Monocrotophos Content (% by mass),MONOCROTOPHOS-36-%-SL(IS:8074-1990)-FSSAI-5902,na,NULL,36 ±5% of the nominal value 
170641,<p>SPECIFIC OPTICAL ROTATION</p>,MONTELUKAST-SODIUM-IP-16520,alphanumeric,+95.0°, +106.0°
170688,DIAMETER,MONTELUKAST-TABLET-(THEON)-IP-16524,na,NULL,8.0 MM ± 0.2MM
170695,HARDNESS,MONTELUKAST-TABLET-(THEON)-IP-16524,alphanumeric,NLT,3.0 KG/CM²
170689,THICKNESS,MONTELUKAST-TABLET-(THEON)-IP-16524,na,NULL,3.90 MM ± 0.3MM
170783,<p>SPECIFIC OPTICAL ROTATION</p>,MOXIFLOXACIN-HYDROCHLORIDE-BP-16533,alphanumeric,-125°, 138°
171081,BACTERIAL COUNT,MULTIVITAMIN-DROPS-(KWALITY)-GENERAL-16554,na,NULL,NMT 10°CFU/GM
171082,FUNGAL COUNT,MULTIVITAMIN-DROPS-(KWALITY)-GENERAL-16554,na,NULL,NMT 10°CFU/GM
171190,<p>SPECIFIC OPTICAL ROTATION</p>,MUPIROCIN-IP-16561,alphanumeric,-17.0°, -21.0°
63888,Bellier Test (Turbidity temp.) ,MUSTARD-OIL-(CSD)-NABL-5945,na,NULL,23.0°C To 27.5°C
66288,Bellier Test (Turbidity temp.) ,MUSTARD-OIL-(FATTY-ACID)-NABL-6070,na,NULL,23.0°C To 27.5°C
39165,Bellier Test (Turbidity temp.) ,MUSTARD-OIL(FSSAI-2006)-FSSAI-4372,na,NULL,23.0°C To 27.5°C
171356,CONDDUCTIVITY,MYO-INOSITOL-(MACLEODS)-GENERAL-16572,alphanumeric,NMT,30.0 ?S CM²
171656,OPTICAL ROTATION,N-ACETYL-L-CYSTEINE-USP-16604,alphanumeric,+21°, +27°
171662,<p>SPECIFIC OPTICAL ROTATION</p>,N-ACETYL-L-CYSTTEINE-BP-16605,alphanumeric,+21°, +27°
50794,Distillation range,N-HEXANE--NABL-5018,na,NULL,NLT 95% distills at 67°C
172334,DISTILLATION RANGE,N-HEXANE-GENERAL-16670,alphanumeric,NLT,95% DISTILLES AT 67°C
171680,METHANOL,NADIFLOXACIN-(RESIDUE)-GENERAL-16606,alphanumeric,NMT,50°µg/g
171682,TOLUENE,NADIFLOXACIN-(RESIDUE)-GENERAL-16606,alphanumeric,NMT,890 µg/g
171681,ACETONITRILE,NADIFLOXACIN-(RESIDUE)-GENERAL-16606,alphanumeric,NMT,41°µg/g
171672,MELTING RANGE,NADIFLOXACIN-(RESIDUE)-GENERAL-16606,alphanumeric,243°C , 251°C
171708,<p>SPECIFIC OPTICAL ROTATION</p>,NANDROLONE-DECANOATE-IP-16609,alphanumeric,+32°, +36°
171736,<p>SPECIFIC OPTICAL ROTATION</p>,NANDROLONE-PHENYLPROPIONATE-IP-16613,alphanumeric,+48°, +51°
171791,<p>SPECIFIC OPTICAL ROTATION</p>,NAPROXCINOD-IP-16619,alphanumeric,+32.0°, +36.0°
171802,<p>SPECIFIC OPTICAL ROTATION</p>,NAPROXEN-IP-16620,alphanumeric,+59.0°, +62.0°
171848,<p>SPECIFIC OPTICAL ROTATION</p>,NATURAL-VITAMIN-E-GENERAL-16625,na,NULL,NLT- +24°
171865,HARDNESS IN KG/CM²,NBISACODYL-GASTRO-RESISTANT-TABLET-(LA-CHEMICO)-IP-16627,na,NULL,NLT 4 KG/CM²
59936,<p>Flash Point (Abel)</p>,NEEM-BASED-EC-CONTAINING-AZADIRACHTIN-0.03-%(IS:14300-1995)-FSSAI-5648,na,NULL,Above 24.5°C
60060,<p>Flash Point (Abel)</p>,NEEM-BASED-EC-CONTAINING-AZADIRACHTIN-0.15-%(IS:14300-1995)-FSSAI-5659,na,NULL,Above 24.5°C
55849,<p>Flash Point (Abel)</p>,NEEM-BASED-EC-CONTAINING-AZADIRACHTIN-1-%(IS:14300-1995)-NABL-5329,na,NULL,Above 24.5°C
171954,<p>SPECIFIC OPTICAL ROTATION</p>,NEOMYCIN-SULPHATE-IP-16637,alphanumeric,+53.5°, +59.0°
172106,<p>SPECIFIC OPTICAL ROTATION</p>,NETILMICIN-SULPHATE-IP-16649,alphanumeric,+88.0°, +96.0°
172352,MELTING RANGE,NIACINAMIDE-(NAXPAR)-GENERAL-16672,alphanumeric,128°, 131°
172342,MELTING RANGE,NIACINAMIDE-USP-16671,alphanumeric,128°, 131°
172382,<p>IDENTIFICATION A</p>,NIACINAMIDE/-NICOTINAMIDE-BP-16674,alphanumeric,128°, 131°C
172554,MELTING POINT,NIMESULIDE-BP-16692,na,NULL,ABOUT 149°C
172659,BACTERIAL ENDOTOXINS,NITROGLYCERIN-INJECTION------(DRUG-CODE-588)-USP-16703,alphanumeric,NMT,NMT 0.1 EU/µg
172671,BACTERIAL ENDOTOXINS,NITROGLYCERIN-INJECTION-(KWALITY)-USP-16704,alphanumeric,NMT,NMT 0.1 EU/µg
172682,BACTERIAL ENDOTOXINS,NITROGLYCERIN-INJECTION-(SAMARTH)-USP-16705,na,NULL,NMT 0.1 EU/µg
172649,BACTERIAL ENDOTOXINS,NITROGLYCERIN-INJECTION-USP-16702,alphanumeric,NMT,NMT 0.1 EU/µg
172875,<p>SPECIFIC OPTICAL ROTATION</p>,NORETHISTERONE-IP-16729,alphanumeric,-33.0°, -37°
172945,HARDNESS IN KG/CM²,NORFLOXACIN-TABLET-(LA-CHEMICO)-IP-16736,alphanumeric,NLT,3.0 KG/CM²
172947,<p>UNIFORMITY OF WEIGHT</p>,NORFLOXACIN-TABLET-(LA-CHEMICO)-IP-16736,na,NULL,[? 7.5% OF AV. WT.]
173107,<p>AVERAGE WEIGHT</p>,NUPHOS-500-INJECTION-(ZEE)-IP-16751,na,NULL,534.5 MG ± 10%
173108,<p>UNIFORMITY OF WEIGHT</p>,NUPHOS-500-INJECTION-(ZEE)-IP-16751,na,NULL,AVG. WT. ± 10%
173413,HARDNESS,O23-BOLUS-(AXEFENDOL-2200-BOLUS)-GENERAL-16781,alphanumeric,11, 13.0 KG/CM²
173818,..PARTICULATE CONTAMINATION,OFLOXACIN-INFUSION-(ACCULIFE)-IP-16820,alphanumeric,GREATER THAN EQUAL , 25°-MAX 60°PARTICLS PER CONTAINER
173817,.PARTICULATE CONTAMINATION,OFLOXACIN-INFUSION-(ACCULIFE)-IP-16820,alphanumeric,GREATER THAN EQUAL , 10°-MAX 600°PARTICLS PER CONTAINER
173927,HARDNESS,OFLOXACIN-TABLET-(KWALITY)-IP-16831,alphanumeric,NLT,6.0 KG/CM²
174228,COLD TEST,OMEGA-3-FATTY-ACID-GENERAL-16856,na,NULL,3h@0°C
174243,ARSENIC,OMEGA-3-FISH-OIL-USP-16857,alphanumeric,NMT,0.1 µg/g
174246,CADMIUM,OMEGA-3-FISH-OIL-USP-16857,alphanumeric,NMT,0.1 µg/g
174244,LEAD,OMEGA-3-FISH-OIL-USP-16857,alphanumeric,NMT,0.1 µg/g
174245,MERCURY,OMEGA-3-FISH-OIL-USP-16857,alphanumeric,NMT,0.1 µg/g
174721,HARDNESS,ONDANSETRON-ORALLY-DISINTEGRATING-TABLET-(BRD)-IP-16898,alphanumeric,NLT,2.0 KG/CM²
174719,<p>UNIFORMITY OF WEIGHT</p>,ONDANSETRON-ORALLY-DISINTEGRATING-TABLET-(BRD)-IP-16898,na,NULL,± 7.5% OF AVERAGE WEIGHT
174908,AVERAGE WEIGHT OF 10 SACHETS,ORAL-REHYDRATION-SALTS-(BP-07)-(KWALITY)-BP-16916,na,NULL,20.5 GM ± 10%
174914,MICROBIAL LIMIT (TVC),ORAL-REHYDRATION-SALTS-(BP-07)-(KWALITY)-BP-16916,alphanumeric,NMT,10°CFU/GM
174978,OPTICAL ROTATION,ORLISTAT-USP-16921,alphanumeric,-48°, -51°
175127,<p>SPECIFIC OPTICAL ROTATION</p>,OSELTAMIVIR-PHOSPHATE-IP-16937,alphanumeric,-42.0°, -48.0°
175236,MELTING RANGE,OXACEPROL-GENERAL-16947,alphanumeric,129.7°C , 131.7°C
175235,<p>SPECIFIC OPTICAL ROTATION</p>,OXACEPROL-GENERAL-16947,alphanumeric,-115.0°, -121.0°
175256,<p>SPECIFIC OPTICAL ROTATION</p>,OXACILLIN-SODIUM-IP-16948,alphanumeric,+196°, +212°
175286,OPTICAL ROTATION,OXALIPLATIN-USP-16950,alphanumeric,+74.5° , +78.0°
175391,MELTING POINT,OXETACAINE-BP-16959,alphanumeric,100,104°C
175517,CONGEALING TERMPERATURE,OXYBENZONE-(BENZOPHENONE-3)-USP-16969,alphanumeric,NLT,62.0°
175639,OXYTETRACYCLINE HCL.,OXYTETRACYCLINE-HCL.-IP-16983,alphanumeric,NLT,835.0 µg (ON ANHYDROUS BASIS)
175630,<p>SPECIFIC OPTICAL ROTATION</p>,OXYTETRACYCLINE-HCL.-IP-16983,alphanumeric,-188.0°, -200.0°
176012,AVERAGE WEIGHT OF FILLED CAPSULE,P21+M17-CAPSULE-SIKKIM-GENERAL-17016,na,NULL,319.0 MG ± 3%
176014,<p>UNIFORMITY OF WEIGHT</p>,P21+M17-CAPSULE-SIKKIM-GENERAL-17016,na,NULL,?10°OF AVG. NET CONTENT
176011,WEIGHT OF 20 EMPTY SHELL,P21+M17-CAPSULE-SIKKIM-GENERAL-17016,na,NULL,1.260°GM ±10%
176010,WEIGHT OF 20 FILLED CAPSULE,P21+M17-CAPSULE-SIKKIM-GENERAL-17016,na,NULL,6.380°GM ±3%
176456,<p>SPECIFIC OPTICAL ROTATION</p>,PACLITAXEL-IP-17069,alphanumeric,-49.0°, -55.0°
176584,HEAVY METALS,PAMABROM-USP-17077,alphanumeric,NMT,20 µg/g
176758,OPTICAL ROTATION,PANTOPRAZOLE-SODIUM-BP-17095,alphanumeric,-0.4° , +0.4°
176740,OPTICAL ROTATION,PANTOPRAZOLE-SODIUM-IP-17094,alphanumeric,-0.40°, +0.40°
176870,HARDNESS,PANTOPRAZOLE-TABLET-(GASTRO-RESISTANT-TABLET-40-MG)-(KWALITY)-IP-17105,alphanumeric,NLT,4.5 KG/CM²
176871,MICROBIAL LIMIT (TVC),PANTOPRAZOLE-TABLET-(GASTRO-RESISTANT-TABLET-40-MG)-(KWALITY)-IP-17105,alphanumeric,NMT,10°CFU/GM
176947,ADHESIVE STRENGTH,PAPER-PLASTER-SIZE-1-INCH-[5306][ESL]-GENERAL-17112,alphanumeric,NLT,11.0 GM/M²
176946,WIDTH,PAPER-PLASTER-SIZE-1-INCH-[5306][ESL]-GENERAL-17112,na,NULL,25.0 MM ±1.0
176955,ADHESIVE STRENGTH,PAPER-PLASTER-SIZE-2-INCH-[5308][ESL]-GENERAL-17113,alphanumeric,NLT,11.0 GM/M²
176954,WIDTH,PAPER-PLASTER-SIZE-2-INCH-[5308][ESL]-GENERAL-17113,na,NULL,25.0 MM ±1.0
176964,TENSILE STRENGTH WIDTH,PAPER-PLASTER-SIZE-3-INCH-[5310][ESL]-GENERAL-17114,alphanumeric,NLT,11.0 GM/M²
176962,WIDTH,PAPER-PLASTER-SIZE-3-INCH-[5310][ESL]-GENERAL-17114,na,NULL,75 MM ±1.0 MM
176940,TENSILE STRENGTH WIDTH,PAPER-PLASTER-SIZE-4-INCH-X-9.1-METER-[10574][ASL]-GENERAL-17111,alphanumeric,NLT,11.0 GM/M²
176972,TENSILE STRENGTH WIDTH,"PAPER-PLASTER,-PAPER-PLASTER-3-9-METER-LENGTH-3-INCH-WIDTH-[5310][ESL]-GENERAL-17115",alphanumeric,NLT,11.0 GM/M²
176970,WIDTH,"PAPER-PLASTER,-PAPER-PLASTER-3-9-METER-LENGTH-3-INCH-WIDTH-[5310][ESL]-GENERAL-17115",na,NULL,75.0 MM ±1.0 MM
176979,ADHESIVE STRENGTH,"PAPER-PLASTER,-PAPER-PLASTER2-9-METER-LENGTH-AND-1-INCH-WIDTH-[5306][ESL]-GENERAL-17116",alphanumeric,NLT,11.0 GM/M²
176978,WIDTH,"PAPER-PLASTER,-PAPER-PLASTER2-9-METER-LENGTH-AND-1-INCH-WIDTH-[5306][ESL]-GENERAL-17116",na,NULL,25.0 MM ±1.0 MM
176987,ADHESIVE STRENGTH,"PAPER-PLASTER,-PAPER-PLASTER2-9-METER-LENGTH-AND-2-INCH-WIDTH-[5308][ESL]-GENERAL-17117",alphanumeric,NLT,11.0 GM/M²
176986,WIDTH,"PAPER-PLASTER,-PAPER-PLASTER2-9-METER-LENGTH-AND-2-INCH-WIDTH-[5308][ESL]-GENERAL-17117",na,NULL,50.0 MM ±1.0
177160,MICROBIAL TESTS,PARACETAMOL-ORAL-SUSPENSION-(KWALITY)-IP-17130,alphanumeric,NMT,10 CFU/GM
177230,BACTERIAL COUNT,PARACETAMOL-SYRUP-(KWALITY)-BP-17137,na,NULL,NMT 10CFU/GM
177231,FUNGAL COUNT,PARACETAMOL-SYRUP-(KWALITY)-BP-17137,na,NULL,NMT 10°CFU/GM
177290,HARDNESS,PARACETAMOL-TABLET-(KWALITY)-BP-17143,na,NULL,NLT 8.0 KG/CM²
177296,MICROBIAL LIMITS (TVC),PARACETAMOL-TABLET-(KWALITY)-BP-17143,na,NULL,NMT 10 CFU/GM
177314,BACTERIAL COUNT,PARACETAMOL-TABLET-(KWALITY)-IP-17144,na,NULL,NMT 10 CFU/GM
177315,FUNGAL COUNT,PARACETAMOL-TABLET-(KWALITY)-IP-17144,na,NULL,NMT 10 CFU/GM
177303,DIAMETER,PARACETAMOL-TABLET-(KWALITY)-IP-17144,na,NULL,12.80 MM ±2%
177309,HARDNESS,PARACETAMOL-TABLET-(KWALITY)-IP-17144,na,NULL,NLT 2.0 KG/CM²
177304,THICKNESS,PARACETAMOL-TABLET-(KWALITY)-IP-17144,na,NULL,4.18 MM ±2%
41529,"Enterobacteriaceae,cfu/gm",PATANJALI-GLUCOSHAKTI-NABL-4547,na,NULL,10°
41530,"Total Fungal Count, cfu/gm",PATANJALI-GLUCOSHAKTI-NABL-4547,na,NULL,10°
177422,<p>NICKEL</p>,PEARLITOL-200-SD(MANNITOL-SPRY-DRIED)-USP-17155,alphanumeric,NMT,1.0 µg/gM
57949,Boiling Point ,PEG-300-NABL-5507,na,NULL,184 to 189°C
177485,<p>PH</p>,PEGYLATED-FILGRASTIM-INJECTION-GENERAL-17161,na,NULL,4.0 ±0.2
177486,PROTEIN CONCENTRATION,PEGYLATED-FILGRASTIM-INJECTION-GENERAL-17161,na,NULL,10.0 ± 1.0 MG/ML
63586,<p>Flash Point (Abel)</p>,PENDIMETHALIN-30%-EC(IS:12751-1989)-FSSAI-5913,na,NULL,Above 24.5°C
63588,Pendimethalin content (% by mass),PENDIMETHALIN-30%-EC(IS:12751-1989)-FSSAI-5913,na,NULL,30 ±5%  of the nominal value
177529,AVERAGE WEIGHT OF 10 CONTAINERS,PENICILLIN-BENZATHINE-INJECTABLE-(KWALITY)-USP-17166,na,NULL,2.045 GM ± 10%
177552,AVERAGE WEIGHT OF 10 CONTAINERS,PENICILLIN-G-SODIUM-INJECTION-(KWALITY)-USP-17168,na,NULL,3.0 GM ± 10%
177878,BACTERIAL COUNT,PHENOBARBITAL-ORAL-SOLUTION-(KWALITY)-USP-17196,na,NULL,NMT 10 CFU/GM
177879,FUNGAL COUNT,PHENOBARBITAL-ORAL-SOLUTION-(KWALITY)-USP-17196,na,NULL,NMT 10 CFU/GM
177957,MELTING POINT,PHENOXYBENZAMINE-HYDROCHLORIDE-BP-17204,alphanumeric,137.5°, 140.0°
40587,"<p>Flash Point, &deg;C</p>",PHENTHOATE-EC-(IS:8291-1976)-NABL-4475,na,NULL,Above 24.5°C
178038,<p>SPECIFIC OPTICAL ROTATION</p>,PHENYLEPHRINE-HYDROCHLORIDE-IP-17211,alphanumeric,-43.0°, -47.0°
178064,OPTICAL ROTATION,PHENYLEPHRINE-HYDROCHLORIDE-USP-17212,alphanumeric,-43.0°, -47.0°
41213,"Material retained on sieve active ingredient, (% by mass)",PHORATE-10%-CG-NABL-4530,na,NULL,10±5% of the nominal value
41210,<p>Phorate Content (% by mass)</p>,PHORATE-10%-CG-NABL-4530,na,NULL,10±5% of the nominal value
178285,AVERAGE WEIGHT OF 10 CONTAINERS,PIPERACILLIN-&-TAZOBACTAM-FOR-INJECTION-(KWALITY)-GENERAL-17236,na,NULL,4.799 GM ± 10%
178482,MICROBIAL LIMITS,PIPERAZINE-HYDRATE-LIQUID-(KWALITY)-GENERAL-17250,alphanumeric,NMT,10 CFU/GM
178662,CLOUD POINT (10°SOLUTION IN WATER),POLOXAMER-188-(KOLLIPHOR-P-188/LUTROL)-USP-17270,alphanumeric,NLT,100.0°C
178682,1-ETHYLENE OXIDE,POLOXAMER-407-(KOLLIPHOR-P-407/LUTROL-F127)-(HETERO)-USP-17272,alphanumeric,NMT,1.0 µg/mg
178683,2-PROPYLENE OXIDE,POLOXAMER-407-(KOLLIPHOR-P-407/LUTROL-F127)-(HETERO)-USP-17272,alphanumeric,NMT,5.0 µg/mg
178684,"3-1,4-DIOXAN",POLOXAMER-407-(KOLLIPHOR-P-407/LUTROL-F127)-(HETERO)-USP-17272,alphanumeric,NMT,5.0 µg/mg
178678,UNSATURATION,POLOXAMER-407-(KOLLIPHOR-P-407/LUTROL-F127)-(HETERO)-USP-17272,na,NULL,0.048 ± 0.017 mEq/g
178680,WEIGHT PERCENT OXYETHLENE,POLOXAMER-407-(KOLLIPHOR-P-407/LUTROL-F127)-(HETERO)-USP-17272,na,NULL,73.2 ± 1.7%
178667,UNSATURATION,POLOXAMER-407-(KOLLIPHOR-P-407/LUTROL-F127)-USP-17271,na,NULL,0.048 ± 0.017
178669,WEIGHT PERCENT OXYETHLENE,POLOXAMER-407-(KOLLIPHOR-P-407/LUTROL-F127)-USP-17271,na,NULL,73.2 ± 1.7%
178691,MELTING POINT,POLOXAMER-407-IP-(LUTROL-F127)-IP-17273,alphanumeric,ABLOUT,56.0°
178806,1-FREE ETHYLENE OXIDE,POLYETHYLENE-GLYCOL-400-(KABI)-USP-17283,alphanumeric,NMT,10 µg/g
178807,"2-1,4 DIOXANE",POLYETHYLENE-GLYCOL-400-(KABI)-USP-17283,alphanumeric,NMT,10 µg/g
178776,1-FREE ETHYLENE OXIDE,POLYETHYLENE-GLYCOL-400-USP-17281,alphanumeric,NMT,10 µg/g
178777,"2-1,4 DIOXANE",POLYETHYLENE-GLYCOL-400-USP-17281,alphanumeric,NMT,10 µg/g
178842,1-FREE ETHYLENE OXIDE,POLYETHYLENE-GLYCOL-4000-(USP/BP)-USP-17286,alphanumeric,NMT,10 µg/g
178843,"2-1,4 DIOXANE",POLYETHYLENE-GLYCOL-4000-(USP/BP)-USP-17286,alphanumeric,NMT,10 µg/g
178896,FREEZING POINT,POLYETHYLENE-GLYCOL-6000-(MACROGOL-6000)-IP-17290,alphanumeric,56? , 60°
178869,1-FREE ETHYLENE OXIDE,POLYETHYLENE-GLYCOL-6000-USP-17288,alphanumeric,NMT,10 µg/g
178870,"2-1,4 DIOXANE",POLYETHYLENE-GLYCOL-6000-USP-17288,alphanumeric,NMT,10 µg/g
179011,HEAVY METALS,POLYOXYL-35-CASTOR-OIL-(KOLLIPHOR)-USP-17305,alphanumeric,NMT,10 µg/gm
178976,CONGEALING RANGE,POLYOXYL-40-HYDROGENATED-CASTOR-OIL-USP-USP-17303,alphanumeric,16°C , 26°C
178995,CONGEALING TEMPERATURE,POLYOXYL-40-STEARATE-USP-17304,alphanumeric,37° , 47°
179039,BURST STRENGTH,POLYPROPYLENE-MESH-STERILE-15X15CM²POLYPROPYLENE-MESH-GENERAL-17309,alphanumeric,NLT,1.9 KG/CM²
179045,BURST STRENGTH,POLYPROPYLENE-MESH-STERILE-6X11-CM²[5293][ESL]-GENERAL-17310,alphanumeric,NLT,1.9 KG/CM²
50795,<p>Viscosity (mPas)</p>,POLYSORBATE-80-NABL-5019,na,NULL,About 40°mPas at 25°C
179285,1-CHLOROFORM,POLYVINYL-ALCOHOL-LIQUID-USP-17324,alphanumeric,NMT,60 µg/gm
179286,"2-1,4 DIOXANE",POLYVINYL-ALCOHOL-LIQUID-USP-17324,alphanumeric,NMT,380 µg/gm
179287,3-METHYLENE CHLORIDE,POLYVINYL-ALCOHOL-LIQUID-USP-17324,alphanumeric,NMT,60 µg/gm
179288,4-TRICHLOROETHYLENE,POLYVINYL-ALCOHOL-LIQUID-USP-17324,alphanumeric,NMT,80 µg/gm
179609,MELTING POINT,POTASSIUM-SORBATE-USP-17355,alphanumeric,ABOUT,270°C
179884,<p>AVERAGE WEIGHT</p>,POVIDONE-IODINE-OINTMENT-(KWALITY)-USP-17377,na,NULL,15 GM ± 9%
180025,DIAMETER,PRALIDOXIME-(PAM)-TABLET-(KWALITY)-USP-17394,na,NULL,10.13 MM ±3%
180033,MICROBIAL TEST (TVC),PRALIDOXIME-(PAM)-TABLET-(KWALITY)-USP-17394,na,NULL,NMT 10°CFU/GM
180026,THICKNESS,PRALIDOXIME-(PAM)-TABLET-(KWALITY)-USP-17394,na,NULL,4.90 MM 0°? 3%
180050,AVERAGE WEIGHT OF 10 CONTAINERS,PRALIDOXIME-CHLORIDE-INJECTION-(KWALITY)-IP-17396,na,NULL,510 MG ± 10%
180105,HEAVY METALS,PRAZIQUANTEL-USP-17401,alphanumeric,NMT,20 µg/g
180141,DIAMETER,PRAZOSIN-TABLET-(KWALITY)-IP-17405,na,NULL,8.0°MM ±2%
180148,HARDNESS,PRAZOSIN-TABLET-(KWALITY)-IP-17405,na,NULL,NLT 3.0 KG/CM²
180151,MICROBIAL LIMIT (TVC),PRAZOSIN-TABLET-(KWALITY)-IP-17405,na,NULL,NMT 10°CFU/GM
180142,THICKNESS,PRAZOSIN-TABLET-(KWALITY)-IP-17405,na,NULL,3.58 MM ±2%
180173,<p>SPECIFIC OPTICAL ROTATION</p>,PREDNISOLONE-BP-17408,alphanumeric,+113°, +119°
180187,<p>SPECIFIC OPTICAL ROTATION</p>,PREDNISOLONE-IP-17409,alphanumeric,+167°, +175°
180407,DIAMETER,PREGABALIN-SUSTAINED-RELEASE-TABLET-(THEON)-GENERAL-17427,na,NULL,9.60 MM ±0.2 MM
180408,THICKNESS,PREGABALIN-SUSTAINED-RELEASE-TABLET-(THEON)-GENERAL-17427,na,NULL,4.20 MM ±0.3 MM
43533,Pretilachlor content (% by mass),PRETILACHLOR-37%-EW-NABL-4650,na,NULL,50.0 ±5% of the nominal value
63760,<p>Flash Point (Abel)</p>,PRETILACHLOR-50-%-EC(IS:15160-2002)-FSSAI-5925,na,NULL,24.5°C
180518,HARDNESS IN KG/CM²,PRIMAQUINE-PHOSPHATE-TABLET-(LA-CHEMICO)-IP-17439,alphanumeric,NLT,2.0 KG/CM²
180519,<p>UNIFORMITY OF WEIGHT</p>,PRIMAQUINE-PHOSPHATE-TABLET-(LA-CHEMICO)-IP-17439,na,NULL,[± 7.5% OF AV. WT.]
180872,MICROBIAL TEST (TVC),PROMETHAZINE-ORAL-SOLUTION-(KWALITY)-BP-17472,alphanumeric,NMT,10 CFU/GM
180860,BACTERIAL COUNT,PROMETHAZINE-ORAL-SOLUTION-(KWALITY)-IP-17471,na,NULL,NMT 10 CFU/GM
180861,FUNGAL COUNT,PROMETHAZINE-ORAL-SOLUTION-(KWALITY)-IP-17471,na,NULL,NMT 10 CFU/GM
41043,<p>Flash Point (Abel)</p>,PROPICONAZOLE-25%-EC-NABL-4519,na,NULL,Above 24.5°C
41045,<p>Propiconazole Content (% by mass)</p>,PROPICONAZOLE-25%-EC-NABL-4519,na,NULL,25±5% of the nominal value
56643,Propoxur content (% by mass),PROPOXURE-20%-EC-(IS:9665-1981)-FSSAI-5402,na,NULL,20°±5% of the nominal value 
180961,<p>SPECIFIC OPTICAL ROTATION</p>,PROPRANOLOL-HYDROCHLORIDE-IP-17479,alphanumeric,-1.0°, +1.0°
181069,IDENTIFICATION (BOILING POINT),PROPYLENE-GLYCOL-(FRESENIUS-KABI-ONCOLOGY-LTD.-BADDI)-GENERAL-17491,alphanumeric,184°, 189°C
181076,IDENTIFICATION (BOILING POINT),PROPYLENE-GLYCOL-(KABI)-USP-17492,alphanumeric,184°C , 189°C
181050,MELTING POINT OF DERIVATIVE,PROPYLENE-GLYCOL-BP-17487,alphanumeric,121° , 128°C
181154,OPTICAL ROTATION,PROTAMINE-SULPHATE-INJECTION-(SAMARTH)-IP-17497,alphanumeric,-0.52° , -0.68?
181246,<p>PARTICLE SIZE</p>,PRUCALOPRIDE-SUCCINATE-(HETERO)-GENERAL-17505,na,NULL,D(0.9) LESS THAN 35 °
181253,<p>SPECIFIC OPTICAL ROTATION</p>,PSEUDOEPHEDRINE-HYDROCHLORIDE-IP-17506,alphanumeric,+61.0°, +62.5°
181334,PARTICLE SIZE DISTRIBUTION,PYCNOGENOL-(SPB-LABS)-GENERAL-17514,alphanumeric,NLT,95% PASSES THROUGH 125 ?m
46533,"<p>Flash Point, &deg;C</p>",PYRETHRUM-EXTRACT-2%-(IS:-1051-1980)-FSSAI-4787,na,NULL,Above 32°C
181426,HARDNESS,PYRIDOSTIGMINE-TABLET-(SAMARTH)-IP-17521,alphanumeric,NLT,3.0 KG/CM²
181484,MELTING RANGE,PYRIMETHAMINE-USP-17528,alphanumeric,238°, 242°
58000,"<p>Flash Point, &deg;C</p>",QUINALPHOS-25%-EC-(IS:8028-1987)-FSSAI-5513,na,NULL,Above 24.5°C
181571,AVERAGE WEIGHT OF 10 CONTAINERS,QUINAPYRAMINE-INJECTION-(KWALITY)-GENERAL-17537,na,NULL,2.593 ±10%
182061,AVERAGE WEIGHT OF 20 CAPSULE SHELLS,RABEDOM-CAPSULE-(KWALITY)-GENERAL-17574,na,NULL,62 MG ± 4 MG
182072,MICROBIAL LIMITS (TVC),RABEDOM-CAPSULE-(KWALITY)-GENERAL-17574,alphanumeric,NMT,10 CFU/GM
182148,AVERAGE VOLUME OF 10 CONTAINERS,RABEPRAZOLE-SODIUM-FOR-INJECTION-(KWALITY)-GENERAL-17581,na,NULL,83 MG ± 10%
182149,AVERAGE WEIGHT OF 5 CONTAINERS,RABEPRAZOLE-SODIUM-FOR-INJECTION-(KWALITY)-GENERAL-17581,na,NULL,83 MG ± 10%
182277,<p>SPECIFIC OPTICAL ROTATION</p>,RAMIPRIL-BP-17592,alphanumeric,+32°, +38°
182265,<p>SPECIFIC OPTICAL ROTATION</p>,RAMIPRIL-IP-17591,alphanumeric,+32°, +38°
182341,HARDNESS,RANITIDINE-HCL.-TABLET-(KWALITY)-IP-17598,alphanumeric,NLT,4.5 KG/CM²
182520,BACTERIAL COUNT,RANITIDINE-TABLETS-(KWALITY)-BP-17613,na,NULL,NMT 10 CFU/GM
182521,FUNGAL COUNT,RANITIDINE-TABLETS-(KWALITY)-BP-17613,na,NULL,NMT 10 CFU/GM
182527,DIAMETER,RANITIDINE-TABLETS-(KWALITY)-BP-17613,na,NULL,10.10 MM ± 3%
182537,HARDNESS,RANITIDINE-TABLETS-(KWALITY)-BP-17613,na,NULL,NLT 2.0 KG/CM²
182528,THICKNESS,RANITIDINE-TABLETS-(KWALITY)-BP-17613,na,NULL,4.80 MM ±3%
40738,"Aflatoxin (B1, B2 & G2, G2)",RED-CHILLI-POWDER-NABL-4495,na,NULL,15 (µg/Kg)
60401,<p>Particle size (% by mass)</p>,RESVERATROL--NABL-5683,na,NULL,NMT 50°
182784,CLOUD POINT,RHODAPON-ALS-25/R-(NAXPAR)-GENERAL-17638,alphanumeric,NLT,12°C
182839,<p>SPECIFIC OPTICAL ROTATION</p>,RIBOFLAVIN-(CIPLA)-GENERAL-17642,alphanumeric,-115.00°, -135.00°(ON DRIED BASIS)
182845,OPTICAL ROTATION,RIBOFLAVIN-(VITAMIN-B2)-USP-17643,alphanumeric,-115°, -135°
182854,<p>SPECIFIC OPTICAL ROTATION</p>,RIBOFLAVIN-5-PHOSPHATE-BP-17644,alphanumeric,+38°, +43°
182821,<p>SPECIFIC OPTICAL ROTATION</p>,RIBOFLAVIN-BP-17641,alphanumeric,-115°, -135°
182809,<p>SPECIFIC OPTICAL ROTATION</p>,RIBOFLAVIN-IP-17640,alphanumeric,-11.5°, -13.5°
182876,<p>SPECIFIC OPTICAL ROTATION</p>,RIBOFLAVINE-5-PHOSPHATE-IP-17646,alphanumeric,+38.0°, +42.0°
182886,<p>SPECIFIC OPTICAL ROTATION</p>,RIBOFLAVINE-SODIUM-PHOSPHATE-IP-17647,alphanumeric,+38.0°, +42.0°
46332,<p>Agaric Acid (ppm)</p>,RICE-FLOUR-NABL-4774,na,NULL,MAX. 10 µg/Kg
46333,<p>Hydrocyanic Acid (ppm)</p>,RICE-FLOUR-NABL-4774,na,NULL,MAX. 5.0 µg/Kg
46334,<p>Hypericine (ppm)</p>,RICE-FLOUR-NABL-4774,na,NULL,MAX. 1.0 µg/Kg
46335,<p>Saffrole (ppm)</p>,RICE-FLOUR-NABL-4774,na,NULL,MAX. 10.0 µg/Kg
182904,HARDNESS,RICHIREEL-TABLET-GENERAL-17649,alphanumeric,NLT,2.0 KG/CM²
183039,<p>SPECIFIC OPTICAL ROTATION</p>,ROCURONIUM-BROMIDE-BP-17660,alphanumeric,+28.5°, +32.0°
183083,<p>3-MASS GM/M2</p>,ROLLER-BANDAGE-(MEDICAL)-15-CM²X-4-MTR.-GENERAL-17663,na,NULL,[57 ± 5 GM/M²]
183211,<p>SPECIFIC OPTICAL ROTATION</p>,ROXITHROMYCIN-BP-17677,alphanumeric,-93°, -96°
183881,HARDNESS,S-AMLODIPINE-TABLET-(KWALI)-IP-17750,alphanumeric,NLT,3.0 KG/CM²
183437,LENGTH,S55-(CR)-TABLET-GENERAL-17704,na,NULL,20.80 mm ±2.0%
183439,THICKNESS,S55-(CR)-TABLET-GENERAL-17704,na,NULL,5.70 MM ±0.2 mm
183438,WIDTH,S55-(CR)-TABLET-GENERAL-17704,na,NULL,9.30 mm ±0.2 mm
183599,<p>IDENTIFICATION A</p>,SACCHARIN-SODIUM-BP-17723,alphanumeric,226°C , 236°C
183683,OPTICAL ROTATION,SALBUTAMOL-SULPHATE-BP-17732,alphanumeric,-0.10°, +0.10°
183717,<p>UNIFORMITY OF WEIGHT</p>,SALBUTAMOL-SULPHATE-TABLET-(LA-CHEMICO)-IP-17735,na,NULL,±7.5% OF AVG. WT.
183809,MELTING POINT,SALICYLIC-ACID-(NAXPAR)-GENERAL-17742,alphanumeric,157°C , 162°C
184015,ARSENIC,SEBIWHITE-(TETRAHDYROCURCUMIN)-GENERAL-17766,alphanumeric,NMT,1.0 PPM (µg/g)
184016,CADMIUM,SEBIWHITE-(TETRAHDYROCURCUMIN)-GENERAL-17766,alphanumeric,NMT,1.0 PPM (µg/g)
184013,HEAVY METALS,SEBIWHITE-(TETRAHDYROCURCUMIN)-GENERAL-17766,alphanumeric,NMT,20 PPM (µg/g)
184014,LEAD,SEBIWHITE-(TETRAHDYROCURCUMIN)-GENERAL-17766,alphanumeric,NMT,3.0 PPM (µg/g)
184006,MELTING RANGE,SEBIWHITE-(TETRAHDYROCURCUMIN)-GENERAL-17766,alphanumeric,85°C , 100°C
184017,MERCURY,SEBIWHITE-(TETRAHDYROCURCUMIN)-GENERAL-17766,alphanumeric,NMT,0.1 PPM (µg/g)
184065,OPTICAL ROTATION,SELENOMETHIONINE-USP-17771,alphanumeric,+17.0°, +19.5°
184229,<p>SPECIFIC OPTICAL ROTATION</p>,SERTRALINE-HYDROCHLORIDE-IP-17787,alphanumeric,+38.0°, 43.0°
184335,LIMIT OF FLUORIDE,SEVOFLURANE-FOR-INHALATION-[1326][T]-USP-17797,na,NULL,NMT 2 µG/ML
184324,LIMIT OF FLUORIDE,SEVOFLURANE-FOR-INHALATION-USP-17796,na,NULL,NMT 2 µG/ML
186033,OPTICAL ROTATION,SORBITOL-SOLUTION-(SOR)-IP-17968,alphanumeric,+1.5°, +3.5°
186052,CONDUCTIVITY,SORBITOL-SOLUTION-70%-(EMCURE)-IP-17970,alphanumeric,NMT,10?S/CM
186066,CONDUCTIVITY,SORBITOL-SOLUTION-70%-(VAPICARE)-IP-17971,alphanumeric,NMT,10?S/CM
186063,<p>SPECIFIC OPTICAL ROTATION</p>,SORBITOL-SOLUTION-70%-(VAPICARE)-IP-17971,alphanumeric,+1.5°, +3.50°
186041,CONDUCTIVITY,SORBITOL-SOLUTION-70%-IP-17969,alphanumeric,NMT,10?SCm
186038,<p>IDENTIFICATION B</p>,SORBITOL-SOLUTION-70%-IP-17969,alphanumeric,+1.5° , +3.5°
185973,LIMIT OF NICKEL,SORBITOL-USP-17963,alphanumeric,NMT,1.0 µg/g
59999,"Enterobacteriacae, cfu/ml",SPECIAL-CHYAWANPRASH-FSSAI-5649,na,NULL,Max. 10°
60000,"Total Fungal count,cfu/ml",SPECIAL-CHYAWANPRASH-FSSAI-5649,na,NULL,Max. 10°
186109,<p>SPECIFIC OPTICAL ROTATION</p>,SPIRONOLACTONE-IP-17978,alphanumeric,-33.0°, -37.0°
186141,<p>SPECIFIC OPTICAL ROTATION</p>,STANOZOLOL-USP-17983,alphanumeric,+34°, +40°
186182,MELTING POINT (?C),STEARETH-2-(AVON)-GENERAL-17988,alphanumeric,42, 46.0°C
186187,CONGEALING TEMPERATURE,STEARIC-ACID-IP-17989,alphanumeric,NLT,54°
186197,CONGEALING TERMPERATURE,STEARIC-ACID-USP-17990,alphanumeric,NLT,54.0°
186252,MELTING POINT,STEARYL-ALCOHOL-GENERAL-17996,alphanumeric,55.0°, 60.0°
186265,MELTING RANGE,STEARYL-ALCOHOL-IP-17998,alphanumeric,55? , 60°
186346,..PARTICULATE CONTAMINATION,STERILE-WATER-FOR-INJECTION-(ACCU)-IP-18006,alphanumeric,LESS THAN 25°,MAX 60°PARTICLS PER CONTAINER
186345,.PARTICULATE CONTAMINATION,STERILE-WATER-FOR-INJECTION-(ACCU)-IP-18006,alphanumeric,LESS THAN 10°,MAX 600°PARTICLS PER CONTAINER
186357,CONDUCTIVITY,STERILE-WATER-FOR-INJECTION-(KWALITY)-USP-18007,na,NULL,NMT 1.3 µs/cm
186380,CONDUCTIVITY,STERILE-WATER-FOR-INJECTION-(OTSUKA)-IP-18009,alphanumeric,NMT,2.0 µs cm
186396,MELTING POINT,STEROL-ESTERS-GENERAL-18010,alphanumeric,31.0°C , 38.0°C
186664,<p>SPECIFIC OPTICAL ROTATION</p>,SUCRALOSE-BP-18038,alphanumeric,+85.0°, +87.5°
186641,<p>SPECIFIC OPTICAL ROTATION</p>,SUCRALOSE-IP-18036,alphanumeric,+84°, +87°
186711,<p>SPECIFIC OPTICAL ROTATION</p>,SUCROSE-(SUGAR)-IP-18042,alphanumeric,+65.9°, +67.0°
186699,<p>SPECIFIC OPTICAL ROTATION</p>,SUCROSE-BP-18041,alphanumeric,+66.3°, +67.0°
186683,CONDUCTIVITY,SUCROSE-USP-18040,alphanumeric,NMT,35 µSCM
186721,LENGTH OF PVC TUBE,SUCTION-CATHETER-(PLAIN)-GENERAL-18043,na,NULL,30 ± 0.1 CM
186774,SULBACTAM SODIUM,SULBACTAM-SODIUM-STERILE-(SAMARTH)-USP-18048,alphanumeric,886, 941 µg/mg (ON ANHYDROUS BASIS)
186755,I-SULBACTAM SODIUM,SULBACTAM-SODIUM-USP-18047,alphanumeric,886, 941 µg/mg (ON ANHYDROUS BASIS)
186754,SULBACTAM,SULBACTAM-SODIUM-USP-18047,alphanumeric,886, 941 µg/mg (ON ANHYDROUS BASIS)
186778,<p>IDENTIFICATION A</p>,SULFAMETHOXAZOLE-BP-18049,alphanumeric,162°, 170°
186807,<p>AVERAGE WEIGHT</p>,SULFASALAZINE-TABLET-[KWALITY]-USP-18052,na,NULL,(LIMIT ± 5%)
186811,HARDNESS,SULFASALAZINE-TABLET-[KWALITY]-USP-18052,na,NULL,NLT 8.0 KG/CM²
186812,MICROBIAL TEST (TVC),SULFASALAZINE-TABLET-[KWALITY]-USP-18052,na,NULL,NMT 10°CFU/GM
50013,Sulphur content (% by mass),SULPHUR-90%-POWDER-FSSAI-4977,na,NULL,90 ± 5% of the the nominal value
54863,<p>Agaric Acid (ppm)</p>,TABLE-BUTTER-(KARAN)-FSSAI-ACT-2006-(2016)-FSSAI-5282,na,NULL,MAX. 10°µg/Kg
54864,<p>Hydrocyanic Acid (ppm)</p>,TABLE-BUTTER-(KARAN)-FSSAI-ACT-2006-(2016)-FSSAI-5282,na,NULL,MAX. 5.0 µg/Kg
54865,<p>Hypericine (ppm)</p>,TABLE-BUTTER-(KARAN)-FSSAI-ACT-2006-(2016)-FSSAI-5282,na,NULL,MAX. 1.0 µg/Kg
54866,<p>Saffrole (ppm)</p>,TABLE-BUTTER-(KARAN)-FSSAI-ACT-2006-(2016)-FSSAI-5282,na,NULL,MAX. 10.0 µg/Kg
187651,<p>SPECIFIC OPTICAL ROTATION</p>,TACROLIMUS-GENERAL-18150,alphanumeric,-110°, -115°
187638,<p>SPECIFIC OPTICAL ROTATION</p>,TACROLIMUS-IP-18149,alphanumeric,-110°, -115°
187702,<p>SPECIFIC OPTICAL ROTATION</p>,TADALAFIL-GENERAL-18154,alphanumeric,+68.0°, +75.0°
187986,<p>SPECIFIC OPTICAL ROTATION</p>,TAPENTDOL-HYDROCHLORIDE-IP-18180,alphanumeric,-24.5°, -28.5°
188005,<p>SPECIFIC OPTICAL ROTATION</p>,TARTARIC-ACID-IP-18181,alphanumeric,-12.0°, +13.0°
188073,OPTICAL ROTATION,TAZOBACTAM-SODIUM-USP-18186,alphanumeric,+160°, +167°
188102,OPTICAL ROTATION,TEA-TREE-OIL-GENERAL-18189,alphanumeric,+5.0°, +15.0°
188292,<p>AVERAGE WEIGHT</p>,TELMISARTAN-TABLET-(THEON)-IP-18203,na,NULL,27°MG ±5.0%
188289,DIAMETER,TELMISARTAN-TABLET-(THEON)-IP-18203,na,NULL,9.50MM ±0.2MM
188296,HARDNESS,TELMISARTAN-TABLET-(THEON)-IP-18203,alphanumeric,NLT,3.0KG/CM²
188290,THICKNESS,TELMISARTAN-TABLET-(THEON)-IP-18203,na,NULL,4.10MM ±0.3MM
188293,<p>UNIFORMITY OF WEIGHT</p>,TELMISARTAN-TABLET-(THEON)-IP-18203,na,NULL,± 5.0°OF AVERAGE WEIGHT
188330,DIAMETER,TELMISARTAN+HYDROCHLOROTHIAZIDE-TABLET-(THEON)-USP-18206,na,NULL,9.50 MM ±0.2 MM
188338,HARDNESS,TELMISARTAN+HYDROCHLOROTHIAZIDE-TABLET-(THEON)-USP-18206,alphanumeric,NLT,3.0 KG/CM²
188331,THICKNESS,TELMISARTAN+HYDROCHLOROTHIAZIDE-TABLET-(THEON)-USP-18206,na,NULL,4.10 MM ±0.3 MM
63751,<p>Flash Point (Abel)</p>,TEMEPHOS-50%-EC-NABL-5923,na,NULL,Above 24.5°C
188477,DIAMETER,TENELIGLIPTIN-TABLET-GENERAL-18216,na,NULL,7.20 MM ±0.3 M
188481,HARDNESS,TENELIGLIPTIN-TABLET-GENERAL-18216,alphanumeric,NLT,2.0°KG/CM²
188478,THICKNESS,TENELIGLIPTIN-TABLET-GENERAL-18216,na,NULL,3.10 MM ±0.3 MM
188648,OPTICAL ROTATION,TERBUTALINE-SULFATE-BP-18230,alphanumeric,-0.10°, +0.10°
188709,LOW BOILING SUBSTANCES,TERPINEOL-BP-18236,alphanumeric,NMT,4.0%V/V DISTILS BELOW 214°C
188707,REFRACTIVE INDEX,TERPINEOL-BP-18236,alphanumeric,1.48, 1.4855 AT 20°C
188708,<p>WEIGHT PER ML</p>,TERPINEOL-BP-18236,alphanumeric,0.931, 0.935 AT 20°C
188722,MELTING RANGE,TESTOSTERONE-ENANTHATE-USP-18238,alphanumeric,34? , 39°
188723,<p>SPECIFIC OPTICAL ROTATION</p>,TESTOSTERONE-ENANTHATE-USP-18238,alphanumeric,+77°, +82°
188758,<p>SPECIFIC OPTICAL ROTATION</p>,TETRACYCLINE-HYDROCHLORIDE-IP-18242,alphanumeric,-239°, -255°
188812,<p>AVERAGE WEIGHT</p>,THEMENTIN-LB-375-TABLET-(THEON)-GENERAL-18249,na,NULL,730 MG ± 5%
188808,LENGTH,THEMENTIN-LB-375-TABLET-(THEON)-GENERAL-18249,na,NULL,17.20 MM ±0.2MM
188810,THICKNESS,THEMENTIN-LB-375-TABLET-(THEON)-GENERAL-18249,na,NULL,5.10 MM ±0.3 MM
188809,WIDTH,THEMENTIN-LB-375-TABLET-(THEON)-GENERAL-18249,na,NULL,8.60 MM ±0.2 MM
188829,<p>AVERAGE WEIGHT</p>,THEMENTIN-LB-625-TABLET-(THEON)-GENERAL-18250,na,NULL,1090 MG ± 5%
188825,LENGTH,THEMENTIN-LB-625-TABLET-(THEON)-GENERAL-18250,na,NULL,17.20 MM ±0.2MM
188827,THICKNESS,THEMENTIN-LB-625-TABLET-(THEON)-GENERAL-18250,na,NULL,6.25 MM ±0.3 MM
188826,WIDTH,THEMENTIN-LB-625-TABLET-(THEON)-GENERAL-18250,na,NULL,9.20 MM ±0.2 MM
188842,DIAMETER,THEOBOS-0.2-(VOGLIBOSE-TABLET-IP-0.2-MG)-(THEON)-IP-18251,alphanumeric,NMT,8.10 MM ±0.2 MM
188848,HARDNESS,THEOBOS-0.2-(VOGLIBOSE-TABLET-IP-0.2-MG)-(THEON)-IP-18251,alphanumeric,NLT,3.0 KG/CM²
188843,THICKNESS,THEOBOS-0.2-(VOGLIBOSE-TABLET-IP-0.2-MG)-(THEON)-IP-18251,alphanumeric,NMT,3.60 MM ±0.3 MM
188857,AVERAGE FILLED WEIGHT,THEOCEF-TZ-1.125-G-INJECTION-(THEON)-GENERAL-18252,na,NULL,1339 MG ± 2%
188858,UNIFORMITY OF FILLED WEIGHT,THEOCEF-TZ-1.125-G-INJECTION-(THEON)-GENERAL-18252,na,NULL,± 2% OF AVF. FILLED WEIGHT
188877,LENGTH,THEOCLAV-625-TABLET-(THEON)-USP-18253,na,NULL,19.80 MM ±0.2 MM
188879,THICKNESS,THEOCLAV-625-TABLET-(THEON)-USP-18253,na,NULL,6.25 MM ±0.3 MM
188881,<p>UNIFORMITY OF WEIGHT</p>,THEOCLAV-625-TABLET-(THEON)-USP-18253,na,NULL,AVG. WT. ± 5%
188878,WIDTH,THEOCLAV-625-TABLET-(THEON)-USP-18253,na,NULL,9.30 MM ±0.2 MM
188915,<p>AVERAGE WEIGHT</p>,THEOMOVE-4-TABLET-(THEON)-GENERAL-18255,na,NULL,30°MG ± 5%
188913,DIAMETER,THEOMOVE-4-TABLET-(THEON)-GENERAL-18255,na,NULL,9.60 MM ±0.3 MM
188914,THICKNESS,THEOMOVE-4-TABLET-(THEON)-GENERAL-18255,na,NULL,4.0°MM ±0.2 MM
188972,DIAMETER,"THEOROS-20-TABLET-(THEON,-BADDI)-IP-18260",na,NULL,9.50 MM ±0.2 MM
188973,THICKNESS,"THEOROS-20-TABLET-(THEON,-BADDI)-IP-18260",na,NULL,3.80 MM ±0.3 MM
188958,DIAMETER,THEOROS-20-TABLET-(THEON)-IP-18259,na,NULL,9.50 MM ±0.2 MM
188959,THICKNESS,THEOROS-20-TABLET-(THEON)-IP-18259,na,NULL,3.80 MM ±0.3 MM
188992,UNIFORMITY OF FILLED WEIGHT,THEOXONE-INJECTION-1.0-G-(THEON)-USP-18261,na,NULL,±2.0°OF AVG. FILLED WEIGHT
189067,<p>SPECIFIC OPTICAL ROTATION</p>,THIOCOLCHICOSIDE-IP-18267,alphanumeric,-550°, -580°
189102,UNIFORMITY OF FILL WEIGHT,THIOPENTAL-SODIUM-INJECTION-(SAMARTH)-BP-18269,na,NULL,±5% OF AVERAGE FILLED WEIGHT
189148,MELTING POINT,THIOUREA-GENERAL-18272,alphanumeric,175°C , 18°C
189213,<p>SPECIFIC OPTICAL ROTATION</p>,THYROXINE-SODIUM/LEVOTHYROXINE-SODIUM-IP-18280,alphanumeric,+16.0°, +20.0°
189227,OPTICAL ROTATION,TIGECYCLINE-USP-18281,alphanumeric,-240°, -215°
189310,<p>SPECIFIC OPTICAL ROTATION</p>,TIMOLOL-MALEATE-IP-18290,alphanumeric,-5.7° , -6.2°
189335,OPTICAL ROTATION,TIMOLOL-MALEATE-USP-18291,alphanumeric,-11.7° , -12.5°
189495,TOBRAMYCIN SULFATE,TOBRAMYCIN-SULFATE-USP-18307,alphanumeric,634, 739.0 µg/mg
189494,TOBRAMYCIN SULPHATE,TOBRAMYCIN-SULFATE-USP-18307,alphanumeric,634, 739.0 µg/mg
189561,<p>IDENTIFICATION B</p>,TOPIRAMATE-IP-18314,alphanumeric,120°, 130°
189562,<p>SPECIFIC OPTICAL ROTATION</p>,TOPIRAMATE-IP-18314,alphanumeric,-28? , -36°
189710,OPTICAL ROTATION,TRAMADOL-HYDROCHLORIDE-BP-18330,alphanumeric,-0.10°, +0.10°
189727,OPTICAL ROTATION,TRAMADOL-HYDROCHLORIDE-IP-18331,alphanumeric,-0.10°, +0.10°
189959,HARDNESS,TRANEXAMIC-ACID-TABLET-(BPPI)-IP-18348,alphanumeric,NLT,2.0 KG/CM²
189998,LIMIT OF ETHYLENE OXIDE,TRANSCUTOL-(DIETHYLENE-GLYCOL-MONOETHYL-ETHER)-USP-18352,alphanumeric,NMT,1 µg/g
56294,Pour point (?C),TRANSFORMER-OIL--FSSAI-5360,na,NULL,Max -6°C
190035,OPTICAL ROTATION,TREHALOSE-USP-18355,alphanumeric,+197.0°, +201°
190097,BOILING POINT,TRIACETIN-BP-18361,alphanumeric,ABOUT,260°C
190114,<p>SPECIFIC OPTICAL ROTATION</p>,TRIAMCINOLONE-ACETONIDE-IP-18363,alphanumeric,+100°, +107°
190286,HARDNESS,TRIHEXYPHENIDYL-HYDROCHLORIDE-TABLET-(ADROIT)-IP-18381,alphanumeric,2, 6.0°KG/CM²
190296,OPTICAL ROTATION,TRIHEXYPHENIDYL-HYDROCHLORIDE(BENZHEXOL-HCL)-IP-18382,alphanumeric,-0.10°, +0.10°
190567,TOTAL PROTEOLYTIC ACTIVITY,TRYPSIN-CHYMOTRYPSIN-GENERAL-18408,alphanumeric,NLT,280µ/mg (ON DRIED BASIS)
190799,EORESIDUALS-A (EO),ULTRAPRO-MESH-(UMR3)-7.6X16CM²GENERAL-18431,na,NULL,MAX.10 µg/g
190800,WATER IN OVEN(WATER),ULTRAPRO-MESH-(UMR3)-7.6X16CM²GENERAL-18431,na,NULL,MAX.100µg
190866,<p>SPECIFIC OPTICAL ROTATION</p>,URSODEOXYCHOLIC-ACID-IP-18438,alphanumeric,+58.0°, +62.0°
190898,HARDNESS,URSODEOXYCHOLIC-ACID-TABLET-(THEON)-IP-18440,alphanumeric,NLT,3.0 kG/CM²
190893,LENGTH,URSODEOXYCHOLIC-ACID-TABLET-(THEON)-IP-18440,na,NULL,17.10 MM ±0.2 MM
190895,THICKNESS,URSODEOXYCHOLIC-ACID-TABLET-(THEON)-IP-18440,na,NULL,5.40 MM ± 0.3MM
190894,WIDTH,URSODEOXYCHOLIC-ACID-TABLET-(THEON)-IP-18440,na,NULL,7.0 MM ±0.2 MM
190904,MELTING RANGE,URSODIOL-(URSODESOXYCHOLIC-ACID)-USP-18441,alphanumeric,200°, 205°
190905,SPECIFIC ROTATION,URSODIOL-(URSODESOXYCHOLIC-ACID)-USP-18441,alphanumeric,57°, 62°
190934,DIAMETER,V.C-500.-&-EPIFORD-(SOD.-VALP.-&-VAL.-ACID-CR-TABLET-(CRESCENT)-GENERAL-18445,na,NULL,13.10 MM± 0.2 MM
190935,THICKNESS,V.C-500.-&-EPIFORD-(SOD.-VALP.-&-VAL.-ACID-CR-TABLET-(CRESCENT)-GENERAL-18445,na,NULL,4.20 MM ±0.2 MM
191044,<p>SPECIFIC OPTICAL ROTATION</p>,VALSARTAN-IP-18459,alphanumeric,-64.0°, -69.0°
191277,AVERAGE WEIGHT OF 10 CONTAINERS,VECURONIUM-BROMIDE-FOR-INJECTION-(KWALITY)-BP-18478,na,NULL,20 MG ± 10%
191257,<p>SPECIFIC OPTICAL ROTATION</p>,VECURONIUM-BROMIDE-IP-18476,alphanumeric,+30.5°, +35.0°
192231,<p>SPECIFIC OPTICAL ROTATION</p>,VITAMIN-D3-IP-18551,alphanumeric,+105°, +112°
192347,.VITAMIN K2-7,VITAMIN-K2-7-POWDER-2500-PPM-GENERAL-18565,na,NULL,MIN.250 µg/g
192350,ARSENIC,VITAMIN-K2-7-POWDER-2500-PPM-GENERAL-18565,na,NULL,MAX. 0.5 µg/g
192352,HEAVY METALS,VITAMIN-K2-7-POWDER-2500-PPM-GENERAL-18565,na,NULL,MAX. 0.5 µg/g
192351,LEAD,VITAMIN-K2-7-POWDER-2500-PPM-GENERAL-18565,na,NULL,MAX.0.5 µg/g
192580,<p>SPECIFIC OPTICAL ROTATION</p>,VOGLIBOSE-IP-18581,alphanumeric,+45.0°, +48.0°
192618,DIAMETER,VOGLIBOSE-TABLET-(THEON)-IP-18586,na,NULL,8.10 MM ±0.2 MM
192624,HARDNESS,VOGLIBOSE-TABLET-(THEON)-IP-18586,alphanumeric,NLT,3.0 KG/CM²
192619,THICKNESS,VOGLIBOSE-TABLET-(THEON)-IP-18586,na,NULL,3.60 MM ±0.3 MM
192622,<p>UNIFORMITY OF WEIGHT</p>,VOGLIBOSE-TABLET-(THEON)-IP-18586,na,NULL,± 7.5% OF AVERAGE WEIGHT
192630,DIAMETER,VOGLIBOSE-TABLET-0.2-MG-(THEON)-IP-18587,na,NULL,8.10 MM ±0.2 MM
192636,HARDNESS,VOGLIBOSE-TABLET-0.2-MG-(THEON)-IP-18587,alphanumeric,NLT,3.0 KG/CM²
192631,THICKNESS,VOGLIBOSE-TABLET-0.2-MG-(THEON)-IP-18587,na,NULL,3.60 MM ±0.3 MM
192634,<p>UNIFORMITY OF WEIGHT</p>,VOGLIBOSE-TABLET-0.2-MG-(THEON)-IP-18587,na,NULL,± 7.5% OF AVERAGE WEIGHT
192800,HARDNESS,WARFARIN-SODIUM-TABLET-(KWALITY)-IP-18600,alphanumeric,NLT,3.0 KG/CM²
192804,MICROBIAL LIMIT (TVC),WARFARIN-SODIUM-TABLET-(KWALITY)-IP-18600,alphanumeric,NMT,10°CFU/GM
62772,<p>Agaric Acid (ppm)</p>,WHEAT-FLOUR-(MAIDA)-NABL-5854,na,NULL,MAX. 10 µg/Kg
62773,<p>Hydrocyanic Acid (ppm)</p>,WHEAT-FLOUR-(MAIDA)-NABL-5854,na,NULL,MAX. 5.0 µg/Kg
62774,<p>Hypericine (ppm)</p>,WHEAT-FLOUR-(MAIDA)-NABL-5854,na,NULL,MAX. 1.0 µg/Kg
62775,<p>Saffrole (ppm)</p>,WHEAT-FLOUR-(MAIDA)-NABL-5854,na,NULL,MAX. 10.0 µg/Kg
60853,Ethyl alcohol content (% by volume 20?/20°34.8?C to 75?C Proof),WHISKY-(SPICY)-NABL-5711,na,NULL,34.8 ± 3 % by volume of the declared strength
57759,<p>Ethyl alcohol content(% by volume 25&deg; under proof at 15/15&deg; C)</p>,WHISKY-&-MALTS-NABL-5491,na,NULL,42.8 ± 3 % by volume of the declared strength
60779,<p>Ethyl alcohol content(% by volume 25&deg; under proof at 15/15&deg; C)</p>,WHISKY(IS:4449-2005)-BIS-5707,na,NULL,42.8 ± 3 % by volume of the declared strength
192880,DROP POINT,WHITE-BEES-WAX-BP-18608,alphanumeric,61.0°C , 66.0°C
192877,MELTING RANGE,WHITE-BEES-WAX-IP-18607,alphanumeric,61.0°C , 65.0°C
58468,<p>Ethyl alcohol content(% by volume 25&deg; under proof at 15/15&deg; C)</p>,WHITE-RUM--NABL-5550,na,NULL,42.8 ± 3 % by volume of the declared strength
192898,MELTING RANGE,WHITE-SOFT-PARAFFIN-IP-18612,alphanumeric,38° , 56°
59301,<p>Agaric Acid (ppm)</p>,WHOLE-WHEAT-ATTA-FSSAI-5594,na,NULL,MAX. 10 µg/Kg
59302,<p>Hydrocyanic Acid (ppm)</p>,WHOLE-WHEAT-ATTA-FSSAI-5594,na,NULL,MAX. 5.0  µg/Kg
59303,<p>Hypericine (ppm)</p>,WHOLE-WHEAT-ATTA-FSSAI-5594,na,NULL,MAX. 1.0  µg/Kg
59304,<p>Saffrole (ppm)</p>,WHOLE-WHEAT-ATTA-FSSAI-5594,na,NULL,MAX. 10.0  µg/Kg
193053,LEAD,XANTHAN-GUM-(MACLEODS)-USP-18627,alphanumeric,NMT,5.0 µg/gM
193028,LEAD,XANTHAN-GUM-USP-18625,alphanumeric,NMT,5.0 µg/gM
193142,MELTING POINT,XYLITOL-IH-(NAXPAR)-GENERAL-18635,alphanumeric,92.0°C , 96.0°C
47942,Ziram Content (% by mass),ZIRAM-27%-CS-(IS-11010:1984)-NABL-4869,na,NULL,27 ±5% of the nominal value
193842,LENGTH,ZOLIMAX-600-TABLET-(THEON)-IP-18707,na,NULL,19.60 MM ±0.2 MM
193844,THICKNESS,ZOLIMAX-600-TABLET-(THEON)-IP-18707,na,NULL,NULL
193843,WIDTH,ZOLIMAX-600-TABLET-(THEON)-IP-18707,na,NULL,9.20 MM ±0.2 MM
193872,HARDNESS,ZOLPIDEM-TABLET-(KWALITY)-IP-18709,alphanumeric,NLT,4.0 KG/CM²
193873,MICROBIAL LIMIT (TVC),ZOLPIDEM-TABLET-(KWALITY)-IP-18709,na,NULL,NMT 10°CFU/GM
